#2469 - Brigham Buhler

98 views

2 months ago

0

Save

Audio

Brigham Buhler

5 appearances

Brigham Buhler is the founder and CEO of Ways2Well, a functional and regenerative care clinic, and owner of ReviveRx Pharmacy. www.ways2well.com www.reviverx.com

ChatJRE - Chat with the JRE chatbot

Timestamps

0:00Austin allergies segue into peptide policy, FDA reclassification efforts, and testosterone/HRT dogma (prostate cancer fears)
9:59Testosterone/HRT dogma, prostate cancer risk, and peptide regulation vs Big Pharma ecosystem
20:15Big Pharma lobbying vs compounding pharmacies: GLP-1s, peptides, patents, and regulatory capture

Show all

Comments

Write a comment...

Transcript

0:00

Joe Rogan Podcast, check it out.

0:03

The Joe Rogan Experience.

0:05

Train by day, Joe Rogan Podcast by night, all day.

0:09

Great. Good to see you, my friend.

0:14

Thanks for having me. We're back.

0:15

My pleasure, always.

0:16

Um, lots going on, man.

0:19

There is a lot going on, per the usual.

0:22

I got fucking allergies, dude. You hear me?

0:25

Oh, yeah, you sound stuffed up. I was going to ask.

0:27

Crazy. I was like, am I getting sick?

0:30

And then I worked out. I'm like, no, I feel great.

0:32

Like, physically, I feel great.

0:34

I don't know what's spiking right now. Do you know?

0:37

I don't know. There's a bunch going on.

0:38

Yeah.

0:38

Everybody's got sore throats.

0:40

It's crazy. They say you don't get it when you live here for, like, a few years.

0:43

And then you start getting it a lot.

0:45

And I was like, I ain't getting it.

0:47

And then about four years in, I started getting these horrible sore throats and

0:52

stuffy noses.

0:53

Is there a peptide for that?

0:55

When I first moved here, the cedar killed me.

0:59

I mean, because Houston doesn't have cedar.

1:01

So it was pine trees in Houston.

1:03

And moving to Austin, the cedar crushed me for the first, like, year and a half.

1:06

And then I got over it.

1:07

My body just got used to it, I guess.

1:09

Yeah, I think my body has to get used to it.

1:11

One thing that does help is colostrum.

1:13

I take colostrum, that arm row.

1:15

Yeah, you can tell the difference?

1:16

Yeah.

1:17

Yeah.

1:17

Makes a big difference.

1:19

Yeah.

1:19

If you take it a lot, take it every day.

1:22

Stay consistent.

1:24

Yeah, I think all of that stuff, there's benefits that so many people overlook.

1:29

I know.

1:30

So, we were talking.

1:32

What's the latest?

1:35

Man, so I know you just had Secretary Kennedy on a few weeks ago.

1:39

Yeah.

1:41

The latest is, you know, hot off the press as of yesterday.

1:45

I know the administration is still working diligently to reclassify peptides.

1:51

I know that that kind of got unveiled on the podcast.

1:54

Man, that has been a labor of love for the last two and a half, three years,

2:00

whatever it's

2:00

been, that we've been trying to get this done.

2:03

And I know I said this when I was on here six months ago, but I'm truly the

2:08

most optimistic

2:09

I've ever been, and with reason.

2:10

I want to, like, temper expectations, but, you know, the prior administration

2:16

of the FDA

2:17

put these things into place prior to Secretary Kennedy and this administration

2:21

taking over.

2:22

It was almost like a Trojan horse.

2:24

They just planted this little bomb in the middle of everything and classified

2:28

these peptides

2:30

as dangerous, and so I've, for the first time in my life, over the last decade

2:37

of 20-something

2:39

years of being in healthcare, you know, the, during, before Secretary Kennedy

2:44

and this group

2:45

of folks were in a position to drive meaningful change, they made these changes

2:49

with the peptides.

2:50

I submitted 17 FOIA requests, 17 to the FDA.

2:55

They have never once responded to a single FOIA request.

2:59

Just asking for clarity about safety and why did we make this decision, and

3:04

they're supposedly

3:05

by law required to respond to this request.

3:08

So to go from that environment where you're being stonewalled and you have no

3:12

accessibility

3:13

and no line of sight and no answers to anything, to being able to at least have

3:17

a seat at the

3:18

table and a voice is pretty revolutionary.

3:21

Well, it's just very helpful that he actually uses them, that Kennedy uses them

3:27

and he knows

3:27

the benefits of them and he's very educated on it, that helps a lot.

3:32

Someone who's actually fit, takes care of himself and uses peptides and

3:36

understands what millions

3:38

of people know.

3:39

Yeah.

3:40

I mean, there's millions of people right now that are taking peptides and it's

3:43

radically improved

3:44

their health and their vitality.

3:45

I agree.

3:46

And I'm one of them.

3:47

I agree.

3:48

Yeah.

3:49

And me too.

3:50

Again, I was the typical American patient.

3:53

I was on the cusp of diabetes.

3:54

I was obese.

3:55

I'm a former fat kid.

3:57

You know, everything that could be going wrong in my late 30s was going wrong

4:02

because I had

4:03

bought into the system and trusted the system and thought, "Hey, if I get my

4:07

blood work annually

4:08

and I follow the doctor's rules," you know, the system's just not built that

4:14

way.

4:14

And that's where I think the nuances of peptides are really difficult for a

4:17

regulatory body like

4:19

the FDA.

4:20

And so to, like, systematically try to break it down for the folks that are

4:24

legacy employees

4:25

at the FDA, I've had that opportunity thanks to this administration and

4:29

Secretary Kennedy

4:30

and his right-hand girl, Stephanie Spear, has been integral in setting meetings

4:37

and trying

4:38

to move the needle.

4:40

Marty McCary, who's the head of the FDA, I had the privilege of knowing him

4:43

before he took

4:44

that role.

4:45

We testified together at the Senate level.

4:48

And Marty, he really is, I don't know if, have you ever read his book?

4:52

No.

4:53

It's called Blind Spot.

4:55

One of the things that I love is I philosophically agree with everything that

4:58

Marty laid out.

4:59

I mean, what he's saying is dogma and that medicine is so worried about

5:05

defending their

5:06

principles and where they stand that they're essentially ignoring at times

5:11

science and they're allowing

5:12

dogma to rule the day rather than letting a pragmatic, authentic, open-minded

5:20

view change

5:21

your perspective and lends on topics.

5:24

And so even with this peptide topic, you know, when I had the opportunity to

5:28

meet with Marty

5:29

on this topic, he said, "Look, Brigham, I didn't really use peptides in my

5:32

practice.

5:33

I was a surgeon.

5:34

You know, it's not something that I'm intimately familiar with, but I'm open to

5:38

understanding

5:39

and trying to research and get a better grasp."

5:43

And some of the moves that this group of folks have already made at HHS, I don't

5:47

know if you're

5:48

following what they did with testosterone and hormone therapy.

5:51

It is literally what you and I talked about at this point, I think five years

5:55

ago, where

5:56

I came on and said, all the shit you're being told on testosterone and HRT and

6:00

hormones, men

6:01

and women, is wrong.

6:03

It's dogma.

6:04

It's been debunked.

6:05

It's not going to cause cancer.

6:06

There shouldn't be black box warnings.

6:08

The FDA has come to the consensus under this new leadership that that is the

6:13

case.

6:13

And they are working to remove the black box warning on hormones.

6:17

They are working to remove the fear mongering around women's hormones and the

6:21

Women's Health

6:22

Initiative and all these things.

6:23

Because we now know what we've been preaching for almost a decade is that these

6:29

hormones are

6:30

a crucial building block that allow us to drive health span.

6:35

And a lot of the decline that we see in our body is because of the hormonal

6:39

decline that

6:40

occurs in our 40s and 50s.

6:41

Could you please expand on the testosterone thing?

6:44

Because one of the things that keeps coming up with people, when I talk to

6:47

friends that

6:48

are older and I say, hey, you know, you should probably get your hormone levels

6:52

checked and

6:53

consider getting on TRT or at the very least getting on something like HCG that

6:57

can increase

6:58

your testosterone.

6:59

It'll really vitalize your health.

7:02

They get concerned with prostate cancer.

7:04

Yeah.

7:05

This is the one that you illuminated and you've helped quite a few of my

7:09

friends understand.

7:10

So please.

7:11

Yeah.

7:12

So all of the fear with prostate cancer literally comes from a study from the

7:17

1930s and it was

7:18

a urologist in the 1930s.

7:20

The patient population of this study, when we talk about random control trials,

7:24

there were

7:24

three patients in the study.

7:26

One patient dropped out.

7:28

One patient was chemically castrated.

7:29

The other patient was normal.

7:31

So the chemically castrated patient, meaning they have no testosterone.

7:35

So if you treat a patient who has no testosterone and you take them from zero

7:40

testosterone to normal

7:42

testosterone.

7:43

So to take them from, let's say, zero to three 50 during that climb from zero

7:48

to three 50,

7:50

you can increase in theoretically the risk of exasperating a prostate cancer

7:57

that's pre pre existing

8:02

was the fear.

8:03

But as you push past that level to optimal levels, you begin to insulate

8:08

against the risk of multiple

8:10

cancers.

8:11

All of the studies henceforth have shown there is not one single study that

8:15

correlates testosterone

8:17

therapy to prostate cancer with an abundance of caution.

8:21

Some urology practices for patients who have had radical prostatectomies are

8:26

reluctant to

8:27

prescribe testosterone, but testosterone in no way, shape or form is causing

8:32

prostate cancer.

8:33

It's a receptor site thing.

8:34

So the best way to explain is you can only water a plant so much, right?

8:38

So once we've saturated the prostate receptor sites with hormones, they're

8:43

saturated.

8:44

And when you push past that to an optimal threshold, you get the insulatory

8:49

benefits of cancer

8:51

reduction that testosterone appears to provide.

8:53

And that's why the FDA is looking to change that label and get rid of the black

8:58

box warnings

8:59

on an array of different things that have been dogma around men and women's

9:03

hormones.

9:04

When you look at this initial study, why was the one person chemically castrated?

9:08

I don't know why.

9:09

This is in the 30s.

9:10

But since then, here's a really real-world example.

9:13

With the boom in testosterone therapy, if there was an increased risk in

9:17

prostate cancer due to hormones, you would have seen a

9:21

skyrocket in the amount of prevalence of prostate cancer in all of these

9:26

practices that are using hormone optimization.

9:29

You don't.

9:30

You see the same prevalence that we saw prior to hormone optimization and the

9:34

boom.

9:35

And so we have now seen, I think it's one out of eight men will develop

9:38

prostate cancer.

9:39

I can't remember the exact number offhand.

9:42

And that correlates exactly the same into the patient population that is on

9:46

hormones.

9:47

Well, the reality is, like, everybody dies with some form of prostate cancer,

9:52

right?

9:53

I don't know.

9:54

I didn't know that.

9:55

Yeah.

9:56

I've heard Huberman talk about that.

9:57

Interesting.

9:58

Yeah.

9:59

Yeah.

10:00

Like, you have a certain amount of it.

10:01

It's just...

10:02

It really became dogma.

10:03

I mean, the study is...

10:04

But I understand about the study.

10:05

Like, so what was the conclusion of the study?

10:06

The conclusion of the study was if we treat men with testosterone, we'll see a

10:10

rise in

10:13

the precursor hormone that we were worried could correlate to increasing the

10:17

risk of prostate

10:18

cancer.

10:19

But the study was...

10:20

And was this only prevalent in this one person that was chemically castrated or

10:22

was it in

10:23

the other guy?

10:24

Correct.

10:25

The other guy who had normal testosterone levels had no increased risk.

10:28

And you have to push through the threshold.

10:30

So think you're at zero and then you're watering the plant.

10:33

Once that plant's watered, it can't take on any more water.

10:36

So from zero, no testosterone, which is chemically castrated.

10:39

You're miserable.

10:40

You have no sexual function.

10:41

You're at increased risk of all these other chronic diseases that can kill you.

10:47

But you're insulated from prostate cancer because you have zero testosterone.

10:51

As we begin to raise your testosterone level and saturate those receptor sites,

10:55

theoretically,

10:56

the concern was we're increasing the potential risk of exasperating of prostate

11:00

cancer.

11:00

So how was this whole opinion based on this one study from the 1930s and just

11:07

repeated ad

11:08

nauseam for decades?

11:09

Well, it wasn't debunked, I think, until the '90s with a famous prominent urologist,

11:14

Dr.

11:14

Morgan Tyler, where he began to do research in his practice on men with

11:18

prostate cancer.

11:19

And he actually began to treat men with prostate cancer with HRT and track the

11:24

results.

11:25

And what he found was there was no increased prevalence of prostate cancer and

11:29

it didn't

11:29

exasperate or create additional issues.

11:32

And so it was debunked in the '90s.

11:34

And then I would even go further to say you launched, I think Pfizer launched

11:38

testosterone

11:39

cream in like 1990-something, I don't remember, and millions of men went on

11:44

testosterone creams.

11:45

If it was exasperating prostate cancer, you would have seen it then too.

11:49

And so now retrospectively, 100 years later, literally 100 years later, the FDA

11:56

and our regulatory

11:57

oversight bodies are now changing their lens on men and women's HRT.

12:03

It's just so crazy that doctors, I've heard doctors, you have to be cautious

12:07

about the

12:08

potential prostate cancer.

12:09

Yeah.

12:10

Like, where do you get this?

12:11

Like, and then you tell them, well, there was a study.

12:14

And so this is the study they're talking about?

12:15

Yeah, that's the study that everyone-

12:16

Three people, one of them dropped out, one of them was chemically castrated,

12:20

and-

12:20

You got it.

12:21

And that guy didn't even get prostate cancer.

12:23

Yeah.

12:24

Please, moving forward, Dr. or Admiral Brian Christine is over the men's health

12:31

initiatives

12:31

over at the FDA, and he's a prominent urologist who has years and years of

12:35

practice of using

12:36

testosterone.

12:37

Marty, I think, even covered hormone therapy in his book, Blind Spot.

12:42

Again, it's a prime example of the dogma of medicine.

12:46

Myth becomes reality, right?

12:48

And misnomer can be adopted, and then it becomes commonplace.

12:52

And now you go to lectures and symposiums where you hear some prominent guy on

12:56

stage regurgitating

12:58

what he was taught in medical school, or she was taught in medical school.

13:01

And then that dogma just perpetuates, and it becomes almost urban legend, which

13:07

is crazy

13:07

to think.

13:08

Yeah.

13:09

That's what it sounds like.

13:10

That's what's nuts.

13:11

Yeah.

13:12

It does sound like urban legend.

13:13

Another quote that, like, resonated with me from Blind Spot was Marty's book.

13:17

Is literally, it's confusing, what was it, dogma with consensus.

13:23

Right?

13:24

When everyone, groupthink is dangerous when it is considered consensus.

13:30

Because groupthink isn't necessarily consensus.

13:32

It's peer pressure.

13:33

To adopt the values and belief systems of your peers and academia.

13:37

And there's an immense amount of pressure to not stray from the herd, to stay

13:41

within the

13:42

herd, to back your peers, to toe the line.

13:47

And we've seen that for the last, what, 20, 30 years.

13:51

If you step out of line, and even back to, you know, originally what spurred

13:54

this were peptides.

13:56

I think a lot of what happened with peptides are that this system is built

14:02

under an entire

14:03

ecosystem.

14:05

It costs $1 billion to $3 billion to bring a drug to market are the numbers

14:10

that are out

14:11

there.

14:12

Anywhere from $1 to $3 billion.

14:14

Now they're taking into account all the drugs that don't make it to the finish

14:17

line.

14:17

But if you really look at the true cost of bringing a drug to market, it's

14:21

still at minimal

14:22

$300 million to $1 billion to bring a drug or a, uh, any sort of technology

14:28

into the marketplace.

14:30

Now that whole ecosystem and structure was built around big pharma and the

14:35

pharmaceutical

14:36

cartels and their attempt to control what hits the market and to protect their

14:42

patents and their

14:43

technologies.

14:44

And so that cost prohibitive process limits, uh, innovation and accessibility,

14:51

um, under the

14:52

name of like protection and safety.

14:55

Um, but in reality, a huge percentage, I guess, one of the things that academia

15:00

will say or

15:01

some of the naysayers around peptides will say is, you know, the issue with

15:05

peptides is

15:06

there's not human control trials.

15:08

The issue with peptides is there's not enough safety data.

15:10

Um, we recently provided the FDA with over 800 different studies that have been

15:15

done on an

15:16

array of the, of the 19 peptides that were banned under the Biden

15:19

administration.

15:20

Um, we've also made them aware that we've submitted 17 FOIA requests to the

15:24

previous administration

15:26

that were never responded to.

15:27

So just seeking clarity and answers.

15:30

Where were you seeing safety issues?

15:32

Because in clinical practice, we just weren't.

15:35

Um, and, and I can tell you at WasteWell now we're at over 90,000 patients

15:40

nationwide and

15:41

peptides were an integral part of our, of, of the practice of WasteWell.

15:44

And we did not see a bunch of adverse events.

15:47

Um, the silence I think speaks for itself.

15:52

I think a lot of it is dogma and confusion and the, the process itself of

15:57

bringing a drug

15:59

to market where I was going with that is, um, I'm not asking the FDA or a

16:04

governing body

16:06

to pay for this for patients, right?

16:08

It's, it's, it's a nuanced difference that I think even regulators are

16:12

struggling to wrap

16:13

their head around.

16:13

We're not asking for Medicare, Medicaid dollars.

16:16

We're not asking for TRICARE dollars.

16:18

We're not asking for the federal government to mandate that employers and

16:22

employer insurance

16:23

programs cover peptides.

16:26

If I'm launching a pharmaceutical drug into the market, I'm asking for

16:29

everything but the

16:30

kitchen sink.

16:30

I'm asking for everybody else to cover the cost of my care and this medication.

16:36

Peptides, proactive medicine, predictive medicine, preventative care,

16:40

personalized medicine is

16:42

all cash pay.

16:43

It is outside of the existing ecosystem and structure.

16:46

And I think that's what makes it so difficult to navigate for regulators

16:52

because it's a new

16:53

world to them.

16:54

If I'm coming from academia where I worked at a hospital where I build insurances

16:58

for the

16:59

last 20 years, and now I'm working at the FDA where everything we do is giant

17:04

pharmaceutical

17:05

companies that love the existing ecosystem because it builds a moat around

17:11

their ability to monetize

17:13

drugs and chronic disease, there's a benefit there to play within that

17:17

ecosystem.

17:17

But if my goal is to bring innovative products to the market at a cost-effective

17:22

price that the

17:23

average person can afford with their own cash, you can't spend a billion

17:28

dollars to do that, especially when

17:31

a molecule is readily available in nature.

17:33

that's where this gets so tricky with things like peptides and stem cells and

17:38

all of these

17:38

products.

17:39

They've kind of been placed in this no man's land and they've been convicted of

17:44

a crime they

17:44

never committed.

17:45

And the truth of the matter is they were put in this no man's land because they

17:49

just don't

17:50

fit in the sandbox of what the system was used to.

17:54

Okay.

17:55

So we should also clarify that when we're talking about peptides and peptides

17:58

being dangerous,

18:00

GLP-1s are peptides.

18:02

This is a gigantic market right now.

18:05

I mean, you're seeing all these ladies that look like they're cutting weight to

18:08

make the

18:09

UFC flyweight division.

18:11

You know, you're seeing everybody that's on these peptides that's losing weight.

18:16

Like, I don't know if Oprah's on them, but she lost a ton of weight.

18:19

I know there's a bunch of celebrities that you see that get Ozempic face.

18:24

Yeah, well, so many influencers too on the academia side go online and go, I

18:30

just, I would

18:30

never prescribe peptides because I'm a board certified clinician and I only

18:35

prescribe things

18:36

that have science and data that back them.

18:39

And yet a lot of times I'd say, man, you might just be uneducated on this topic

18:44

and the nuances

18:45

of this topic.

18:46

In reality, most clinicians are prescribing drugs off label, right?

18:51

So a huge percentage of medical practices use products off label.

18:55

It's indicated for one thing or one patient population or a dosage or a chronic

18:59

disease

19:00

state, but clinicians have the autonomy and the authority to use that drug in a

19:05

manner that

19:06

it's not indicated for.

19:07

And they do that every day.

19:09

It's almost time for spring break.

19:10

So maybe you're headed to the beach or maybe you're taking the kids on a road

19:14

trip, or maybe

19:15

you're just taking some extra time for yourself.

19:17

No matter what, you deserve a break and a reset and AG1 can help.

19:21

AG1 is your daily health drink.

19:23

Just one scoop combines your multivitamin, pre and probiotics, superfoods and

19:29

antioxidants

19:30

to help support a healthy immune system and digestion.

19:34

Plus it travels really well.

19:36

So you can start working it into your routine, even when you don't have a

19:39

routine, just slip

19:40

a few travel packs into your luggage and have a nice flight.

19:43

I've talked about AG1 for a long time and it's not just me.

19:47

I know a lot of people enjoy it.

19:49

It's very easy.

19:50

It's very convenient and you deserve to take care of your health.

19:54

Visit drinkag1.com slash Joe Rogan and for a limited time, get a bottle of

20:00

omega-3 vitamin

20:01

D3 K2 and an AG1 flavor sampler for free in your welcome kit with your first

20:07

subscription.

20:09

That's an $111 value at drinkag1.com slash Joe Rogan.

20:15

Well, this was the big challenge during COVID, right?

20:18

With hydroxychloroquine and with ivermectin.

20:20

Yep.

20:21

That was the big challenge.

20:22

And the real problem is that it interferes with the potential profits of

20:26

pharmaceutical

20:27

drugs that are approved.

20:29

So if you give someone the option to take something that's off-labeled, that's

20:33

less expensive,

20:34

and then they find out it's effective, and then it gets public, you find out

20:39

there's less

20:40

people that are taking whatever pharmaceutically approved drug.

20:43

Correct.

20:44

And so what created this backlash or momentum against peptides, candidly, were

20:51

the GLP-1 weight

20:52

loss drugs.

20:53

So I do want to put them in two different buckets because there's the 19 peptides

20:57

that got moved

20:58

to the dangerous list with no clear answer from the previous administration as

21:03

to why or how.

21:04

But what I have seen from being able to get behind the scenes and meet with

21:08

lobbyists and

21:09

legislators at the state and federal level is the lobbying power of Big Pharma

21:13

is real.

21:14

It's real, and it's intense, and it is not going away.

21:17

It's a lot of money.

21:18

And so to put myself in the shoes of somebody, you know, like I've gotten to

21:23

know Chris Klump

21:24

really well at the FDA, and Chris negotiated the most favored nation pricing on

21:28

the pharmaceutical

21:29

drugs with Lilly and Novo and all these big conglomerates.

21:32

And those companies definitively, you know, publicly and privately are banging

21:37

on the table

21:38

of legislators and politicians and saying, look, we spent billions of dollars

21:42

to innovate

21:43

these drugs.

21:44

We played within the rules of the system.

21:46

And now these drugs hit the market, and you're allowing compounders and small,

21:52

independent

21:53

pharmacies to rip off our patents, right?

21:56

And that's their stance, and they plant that stake way over here.

21:59

If that regulator only hears that part of the story, it's a compelling story.

22:05

You look at it and go, God, man, poor Big Pharma.

22:06

They spent all this money.

22:08

But if you zoom out and you know the lay of the land a little bit more, which

22:11

is hard if

22:12

you don't come from this industry, the truth is always in the middle.

22:16

So devil's advocate, of course, you want to protect the patent rights of a

22:21

company that

22:22

spent billions of dollars to bring a drug to market.

22:25

We've covered this before, though.

22:27

The dirty secret is a large majority of the drugs that come to market come from

22:31

the NIH, and

22:33

phase one trials are done at the NIH.

22:35

The NIH is funded by taxpayer dollars.

22:38

You and I are paying to innovate and create molecules that then get licensed

22:43

off to big

22:44

pharmaceutical companies so they can bring them through the FDA approval

22:47

process.

22:48

How is that legal?

22:50

It's nuts.

22:51

That is wild.

22:52

Yeah, it's nuts.

22:53

And so I was trying to explain to the existing team at HHS, zoom out.

23:01

The system, as much as you are being told failed and let Big Pharma down and

23:08

allowed people

23:09

to come in and infringe upon these patents, the truth of the matter is the FDA

23:13

sent out the

23:14

bat signal and said, we can't meet the need of the American people.

23:19

There is a backlog on these drugs.

23:21

It's on the backlogs list.

23:23

Can compounders make these drugs?

23:25

This has been a regulatory pathway that's been in existence for 30, 40 years.

23:30

It happens all the time.

23:32

So compounders respond to the bat signal, begin to make these medications to

23:37

the benefit of

23:38

the American people during the shortage list.

23:41

And then you have these big pharmaceutical companies going, look, they're

23:44

making our drugs.

23:45

They're violating our patent.

23:46

If your concern is that these companies didn't get the juice worth the squeeze

23:51

from the patent,

23:52

Eli Lilly 7xed the value of their company.

23:56

They're worth $800 billion.

23:58

They literally are worth more than most developed nations.

24:03

This was the biggest blockbuster molecule in the history of the world, in the

24:09

history of humanity.

24:11

There has never been a drug that is this big of a blockbuster.

24:14

The money was made 50,000 times over.

24:18

Nobody was harmed.

24:21

But when I'm a legislator and I've got somebody telling me, these guys heard us

24:25

to the tune

24:26

of $7 billion, and I know that's what they're telling these legislators,

24:29

because I've met

24:30

with the legislators at the state and federal level.

24:32

And then I have to go, well, hold on.

24:33

The entire compounding sector only does $7 billion.

24:37

GLP-1s were $2.5 billion.

24:40

I know that's a big number, but that was when you were asking us to make these

24:44

compounds.

24:45

That number's not nearly as large today, and you also shut down 503Bs, which is

24:51

half of

24:52

the compounding industry's ability to make these compounds.

24:54

The truth of the matter is, it's about $1.5 to $2 billion total that this

24:59

industry was able

25:01

to compound during the backlog in order to meet the needs of the American

25:05

people.

25:05

They're going to do $35 to $40 million in just GLP-1 drugs this year in revenue.

25:14

So, you're talking an accounting error for big pharma.

25:17

And the reason I want to lay all that out is, I'm not here to argue about the

25:21

GLP-1s.

25:21

It sets a dangerous precedent.

25:23

If pharma lobbies hard enough and they're able to get this done, like what they

25:28

want to do,

25:29

reclassifying all these as biologics, it allows them to extend the patent for

25:33

10 to 12 years.

25:34

It's this whole shell game, but it sets precedent like we covered before, and

25:39

that precedent is

25:40

dangerous.

25:40

It's a slippery slope because if you do totally shut out compounders from their

25:45

ability to make

25:46

this for the American people, how long before they move to the next thing?

25:49

And in one breath, you've got big pharmaceutical companies saying, I'll use

25:53

Lilly again as an

25:54

example because they're the main culprit.

25:56

Lilly is saying, peptides are dangerous.

25:59

They're getting the API from China.

26:02

We shouldn't allow these compounders to make peptides.

26:04

Meanwhile, Eli Lilly just signed a $7 billion deal to acquire a peptide company

26:12

out of China.

26:13

China.

26:15

So, Lilly's buying a peptide company from China while lobbying government

26:20

officials and saying

26:21

it's dangerous to use products from China, and these compounders are dangerous,

26:25

and nobody's

26:26

regulating it.

26:27

And there's just all this misnomer and dogma, and it's confusing if you don't

26:32

come from healthcare.

26:33

Well, it seems like it would be very confusing for a regulator.

26:36

Very confusing for someone who's not educated on this to get up to speed.

26:42

100%.

26:42

And they have so many initiatives and so many things they're tackling.

26:45

And then the challenge historically is when you're big pharma, and I think it

26:49

was like $31 million

26:51

that that industry used in lobbying power last year as an industry, dollars

26:57

equal accessibility,

26:59

accessibility equals impressionability, and impressionability equals outcomes.

27:04

It's like trying to win a debate where I get one minute and the opposition gets

27:08

nine minutes.

27:10

And in the one minute, I've got to debunk all the lies that the opposition told.

27:14

Now, I don't even want to use the word lies.

27:15

You can use facts, but like we've said before, facts can be skewed when

27:20

delivered inappropriately.

27:22

If you say they cost us $7 billion, and we spent $3 billion to bring this drug

27:26

to market,

27:27

and they're importing products from China, and there's no safety nets, and

27:30

nobody's inspecting

27:32

them, and this is what we're worried about.

27:33

This is dangerous, and this is a liability to the American public.

27:37

Politicians ears are going to perk up, especially when you're lobbying them and

27:41

funding campaigns

27:42

and trying to influence those folks.

27:44

But the truth is, yeah, if you take into account all the drugs that didn't make

27:50

it, and you

27:50

want to cook the books, you can make it look like you spent a billion to $3

27:54

billion.

27:54

You can also take credit for all the drugs that were launched out of the NIH

27:58

that you bought

27:59

the rights to and monetized for decades.

28:02

And then you can talk about safety, but in reality, there were recalls from

28:07

both Lilly and

28:08

Novo Nordisk.

28:09

There are all sorts of array of issues and label changes, and historically,

28:14

even the FDA itself.

28:15

This is one of the things with peptides that when I met, when I had the

28:17

privilege of meeting

28:18

with Marty McCary about, I said, Marty, if we're being honest, this is y'all's

28:24

numbers.

28:25

60% to 80% of the drugs that make it through the drug approval process will

28:29

have a major label

28:31

change or recall.

28:32

60% to 80% of the medications that come through this process end up having a

28:39

major label change

28:41

or recall.

28:42

What is a major label change?

28:44

So they uncover, like, an example with antidepressants, they realize the

28:51

suicidal ideation in teenagers,

28:53

right?

28:53

And they had to change that label and say, hey, not only is this only a

28:57

fraction better than

28:59

a placebo, right?

29:00

Barely differentiates from placebo retrospectively.

29:03

And not even close to exercise.

29:04

I know.

29:05

It's literally, exercise is six to sevenfold more efficacious than an antidepressant.

29:10

How wild is that?

29:11

Yeah.

29:11

And then you go back to the science.

29:13

The science was all cooked books.

29:15

It was all said that it was serotonin related.

29:18

And there was never a single study that correlated depression to serotonin.

29:22

It was all dogma created by industry.

29:25

And so, again, Marty talks about this in his book.

29:28

So I know he's aligned with a lot of these viewpoints.

29:30

When it comes down to peptides, though, it gets a little confusing because you're

29:35

talking

29:36

proactive, predictive, preventative care.

29:38

If somebody's taking a peptide to optimize their healing, it's not a chronic

29:43

disease related

29:44

issue.

29:45

The system is built to monetize and profiteer off of treating the symptoms of

29:49

chronic disease.

29:51

It's become a prescription management system, not a health care system.

29:56

And that's the big challenge.

29:57

This is an entire paradigm shift that I don't know if all regulators truly

30:03

understand.

30:05

I think they're trying to wrap their head around it.

30:07

I think Secretary Kennedy understands it.

30:09

I think a lot of this movement in the American people post-COVID have

30:13

fundamentally changed.

30:15

Like the view that I've seen is people do now question authority.

30:20

People do now question just because something came through the FDA doesn't mean

30:24

it's safe.

30:24

And just because something hasn't gone through the FDA approval process doesn't

30:28

mean that it's

30:29

dangerous or doesn't work.

30:30

A lot of times there's a reason why, like BPC-157.

30:34

There's a patent out of Croatia, I believe, on that molecule.

30:38

And that patent is, I think, last three more years.

30:41

Why would you go spend a billion to three billion dollars to try and bring a

30:46

drug to market that

30:47

already has a patent?

30:48

The other issue with it is a short-chain amino acid peptide found readily in

30:52

nature.

30:53

And patent law makes it very difficult to patent what is naturally found in

30:58

nature.

30:58

And that is why the big pharmaceutical companies are struggling with their

31:03

patents on the GLP-1s.

31:04

They have patented dosaging and delivery mechanisms.

31:07

They're not arguing against the patent.

31:10

If you look at the lawsuits that they filed nationwide, they're arguing against

31:14

people advertising.

31:15

They're arguing against some of the things people shouldn't be doing, rightfully

31:19

so, but

31:21

they're not arguing against the patent.

31:22

Let me ask you this.

31:23

So just imagine, and I don't think this is a good idea, but imagine if only

31:28

pharmaceutical

31:29

drug companies were allowed to make peptides, would they just become legal?

31:33

Yeah.

31:34

Yeah.

31:36

Yeah.

31:36

I mean, well, what would happen?

31:37

Well, there would be a giant business.

31:38

It would be a giant business, and it is going to be a giant business.

31:41

The price would raise a little bit.

31:42

Yeah, 100%.

31:42

But also, the availability would skyrocket, and you would start seeing

31:47

commercials on CNN.

31:49

Yeah.

31:49

EPC-157 helps soft tissue injuries.

31:52

Yeah.

31:52

Helps this, helps that.

31:53

Then you'd throw fit people at the beach jogging.

31:56

Yeah.

31:56

Yeah.

31:57

And I agree with you, but the fear, and this is what I'm trying, I'm viewing it

32:02

as there's

32:03

three options, and these are the three things that I've seen.

32:06

There's the traditional system, the sick care system.

32:09

That system is controlled by insurance, big pharmaceutical companies, and

32:12

regulators.

32:13

Whether intentional or unintentional, this system was cooked.

32:17

It's been cooked and baked for a long time, and it is the system that it is.

32:21

And we know where that system got us.

32:23

That system got us to 1.7 to 1.9 million Americans dying every year of chronic

32:29

disease,

32:29

more than every world war we've ever fought.

32:31

It's got us to be the most obese and disease-riddled society in the history of

32:35

humanity, and we

32:37

spend more on health care than any other nation.

32:39

So that's one option.

32:41

Just that.

32:41

And then we go-

32:42

Just those facts are so crazy.

32:44

It's nuts.

32:45

And to think that to ask questions or to challenge that system is wrong, and

32:50

that's where I am.

32:51

I'm so, again, I'm not sitting here, I'm not trying to make this political,

32:56

because I really

32:57

am not, I don't care, conservative, Democrat, Republican, chronic disease doesn't

33:02

care about

33:03

your political leanings.

33:04

It doesn't care.

33:05

Like, disease and death comes for all of us, and my goal is how do we prevent

33:10

it?

33:10

How do we delay it?

33:11

How do we drive health span?

33:13

You don't do it playing whack-a-mole and treating the symptoms of a chronic

33:17

disease.

33:18

You get proactive, predictive, and preventative.

33:20

And how do you do that?

33:22

Well, you've got to be able to run diagnostic tests and tools.

33:24

Well, the insurance companies shut that down and make that really hard to do.

33:29

And so in the health care system that exists today, in the insurance model,

33:33

prescription

33:35

management is the main goal of those models.

33:40

And I've said this time and time again, you've got to view health insurance in

33:44

America like

33:45

car insurance.

33:46

It's there if you wreck the car.

33:48

We are great at triaging and treating a catastrophic event, heart attack,

33:53

stroke, hospitals.

33:54

You're in there, something catastrophic happens, we can triage that disaster,

33:59

and we can get

33:59

you in and out of the hospital.

34:00

We are absolutely an abysmal failure at preventing chronic disease and driving

34:08

health span.

34:09

And the only way to do that is to get proactive and predictive and personalized.

34:14

And this entire ecosystem is just not built to do that.

34:19

And so my message and what I'm trying to work for is so much bigger than peptides.

34:24

I don't want to die on the peptide hill fighting for this, because it is a

34:28

small sliver of what

34:29

could be our health care establishment, right?

34:32

When we look at biologics, when we look at gene activation, all of these

34:37

different modalities

34:38

that are on the table, large language models, artificial intelligence, tracking

34:43

data in real

34:43

time, we have the ability to truly drive health span now.

34:48

If I have your genetic sequencing and your blood work and your biomarkers and

34:54

your DEXA and

34:55

your VO2 max, and I put all that into the AI algorithm and we begin to track

35:00

you in real

35:01

time in your 30s, we are going to know years before a chronic disease ever

35:05

shows up on your

35:06

doorstep.

35:07

The cancer that you get in your 40s started in your 30s, you know, the diabetes

35:11

you get

35:12

in your 30s started in your 20s.

35:13

All of this is preventable.

35:15

All of this is preventable through diet, lifestyle, and nutrition.

35:18

We're not under-prescribed.

35:20

I think that's pretty abundantly clear.

35:22

The average American's on four or more prescription drugs.

35:25

Like, we can't prescribe our way out of this.

35:28

Is that a real number?

35:29

Yes.

35:29

The average American is on four or more prescription drugs?

35:32

Which is insane, and it is because we're a prescription-first society, right?

35:38

And we've covered this before, so I hate to beat a dead horse, but, like, when

35:42

a primary

35:42

care has six minutes on average with a patient and they're limited in what

35:46

tests they can do

35:47

and what diagnostic tools they can run, and a woman comes in and says, hey, I'm

35:52

40 pounds

35:53

overweight, I'm depressed, I'm anxious, I'm sad, I'm all these things, their

35:59

first move

36:00

is to go, okay, well, we've got to get your cholesterol under control, we've

36:02

got to get

36:03

your insulin under control, I'm going to put you on a weight loss drug, let's

36:05

put you on

36:05

a GLP-1, and they push them out the door, and they probably put them on an antidepressant

36:09

because those are the tools in their tool belt.

36:11

But if you were to come into a longevity-based clinic, we're going to run you

36:16

through a battery

36:16

of diagnostics.

36:17

So many men come in depressed, you're not really, it's not to trivialize your

36:21

depression.

36:22

It isn't that you're depressed, it's that you have a hormonal imbalance, and

36:26

your hormones

36:26

are so wrecked that you're obese.

36:28

Are you obese because your hormones are wrecked, or are your hormones wrecked

36:32

because you're

36:32

obese?

36:33

You know, sometimes that's going to take a nuanced approach and time to uncover,

36:37

but we

36:38

do know we can fix that, you know, and we know that through fixing those things,

36:42

there's

36:42

going to be a cascade of benefits that lead into other areas of your life.

36:46

Like, Jelly Roll's a prime example.

36:47

If he were to go to a primary care, they would have immediately put him on a GLP-1.

36:51

He's 500 pounds, you know, and they would have put him on a battery of drugs.

36:57

When Jelly Roll came to us, it was like, we're going to make this simple.

37:01

We got to fix your insulin.

37:02

We got to fix your hormones.

37:04

That's it.

37:05

We're going to get your estrogen under control.

37:06

We're going to get your insulin under control.

37:08

We're going to get your inflammation under control.

37:10

We're going to put wins on the board, and we're going to methodically walk you

37:14

through

37:14

this, because people think that, this is the other challenge, even where I was

37:19

going earlier,

37:20

even in the longevity space, the preventative care space, it's already becoming

37:25

what Big

37:26

Pharma was.

37:27

And this is one of my really big heartburns.

37:29

You've got two pathways.

37:31

See, the first, the three pathways.

37:33

The first is the traditional system.

37:34

The second is the cash pay model.

37:36

Okay, well, that's kind of merging into two different arenas.

37:40

You've got the Peter Atiyah's $100-something thousand dollars to be my client

37:45

that only the

37:46

richest Americans can afford, and you're going to get top-tier care, and I'm

37:50

going to provide

37:51

concierge medicine.

37:52

Well, 99.99% of America can't afford that.

37:55

And then you've got the hymns of the world that are going the route of a pill

37:59

mill.

38:00

Like, candidly, it isn't about quality of care.

38:03

It isn't about helping patients solve a problem.

38:06

It's about monetizing a medication and putting a weight loss drug or a peptide

38:12

as fast as

38:12

possible in that patient's hand so you can monetize the patient.

38:15

To me, that's no bigger, different than Big Pharma.

38:18

And so my vision for the future is how do we combine the best of both worlds?

38:25

How do we take that nuanced concierge care, make it affordable, make it

38:30

scalable, and make

38:32

it truly drive healthspan?

38:33

I don't think the issue is the arrow.

38:36

The issue is the archer.

38:37

It's the people controlling these systems and always trying to make it about

38:41

money and quarterly

38:42

earnings and an exit and a strategy.

38:44

But if you pivot and you make it about people, and you make it about how do we

38:48

help this person,

38:49

the journey of a thousand miles starts with the first step.

38:53

And Jelly is a perfect example.

38:56

If you were in a traditional model, he would come in and you would sell him a

38:59

weight loss

39:00

drug, and that's the end of your journey with him.

39:02

You get him on a weight loss drug and you hope for the best and you push him

39:06

out the door.

39:07

In our model, we're there to be a passenger alongside you, using large language

39:12

models,

39:12

wearables, and all the things we're bringing into the business to track,

39:17

diagnose, and optimize

39:19

where you're at in real time.

39:21

So in real time, we're able to capture how are you trending.

39:24

We even added a scale that ties into the app that will allow you to manage your,

39:29

not just

39:30

your BMI, but literally almost like a DEXA with like a 1 to 2% variability rate.

39:35

We can tell you how much lean fat, how much visceral fat, how much subcutaneous

39:39

fat, and

39:40

anyone who's a member gets that scale, scans it into the app.

39:43

That combined with your VO2 max, if you come into the clinic, we can cross-reference

39:47

it with

39:48

a DEXA.

39:48

The app will do its own algorithms to see how different it is.

39:52

And now in real time, from your home, you can track all these modalities and

39:57

you can track

39:58

how you're trending on more than just blood work.

40:01

Like to me, everyone, again, when I came on here, whatever, I think it was five

40:07

years ago

40:08

by now, Joe, nobody was doing cash pay blood work.

40:10

Now everybody's doing cash pay blood work.

40:13

And I think it's great, but it isn't the holy grail.

40:16

That's just one marker in a sea of markers, one diagnostic measuring stick in a

40:22

sea of diagnostic

40:23

measuring sticks.

40:24

So the future for me is how do we make it affordable and how do we make this

40:28

where everyone can afford

40:29

it?

40:30

One of the things we're going to do is put our money where our mouth is.

40:32

You're going to be able to load your blood work from anywhere.

40:35

I don't care if you got it at your doctor, your primary care, if you got it

40:38

from HIMSS,

40:39

if you got it from function health, doesn't matter.

40:42

If you want a nuanced approach and help on your healthcare journey, not the

40:46

first step,

40:47

you took the first step, you did the blood work.

40:49

Now, what do you do with that data?

40:51

What do you do with that information?

40:54

Even in the longevity space where I was going with that is so many companies

40:57

are trying

40:57

to let me monetize this blood work.

40:59

Let me monetize this test.

41:01

Let me monetize this peptide.

41:04

But what we should be asking is, how do I help this patient?

41:06

How do I help this person?

41:09

Because if you help that person, they tell the fucking world.

41:12

I think the problem is, like, you're an actual good dude.

41:17

You're an actual good person.

41:18

I'm trying.

41:21

There's a lot of days I don't know.

41:22

But you are.

41:23

I've known you for a long time now.

41:25

And you really are doing what you're saying.

41:29

I know you could be making a whole lot more money than you're making.

41:32

And I know you're not money driven.

41:34

But that's not the business of healthcare.

41:37

That's not the business of all these different companies.

41:40

When they exist, especially if they're public, if these are public companies,

41:43

they have an obligation to their shareholders.

41:45

They have to maximize their profits.

41:47

And, you know, it's so fucking hippie to say this.

41:51

The root of all evil.

41:53

It's real.

41:54

I mean, that is a real thing.

41:55

Like, there's nothing wrong with money.

41:57

But there is wrong with the motivation that comes with money,

42:00

that you put money above everything else.

42:02

I mean, I know Waste of Well is doing great,

42:05

and I know you're making plenty of money.

42:07

But most companies are only trying to do that.

42:11

Whereas you are trying, legitimately trying, to make people.

42:16

But I know, I see the look on your face when people get better.

42:19

I love this stuff, man.

42:21

I know you do.

42:21

I really love it.

42:22

I know you do.

42:23

And like Denise and I said from day one,

42:24

I've known Denise, I mean, 20-something years, man.

42:28

And when we started this, she's my Jiminy Cricket.

42:31

Because even if I ever wanted to make it about money,

42:35

she's never making it.

42:36

She's such a patient care advocate.

42:38

And I said, and she said,

42:41

if we always make this about people,

42:43

there's going to be days we lose,

42:44

there's going to be days we win.

42:45

But if we always make it about people,

42:47

if we make people our northern star,

42:49

that is our secret sauce.

42:51

And it doesn't mean we're perfect.

42:53

Like, look, every time I come on here,

42:54

we get blasted because we grow so fast.

42:56

And it's a blessing.

42:57

And I can't thank you enough.

42:59

But, you know,

43:00

you can't onboard 20,000 people overnight.

43:03

And then people are like,

43:04

oh, you guys suck.

43:05

Y'all are like everybody.

43:06

And it's like, no, man.

43:07

We just, even as we're growing,

43:09

this is, again, back to that dogma of like,

43:12

how are companies like HIMS scaling nationwide?

43:15

They're PE backed.

43:17

BlackRock is one of their biggest investors.

43:20

HIMS is a multibillion dollar conglomerate marketing firm.

43:24

They're not a compounding facility.

43:26

They're not a medical practice

43:28

with brick and mortar clinics

43:29

that are trying to truly innovate

43:32

and that are into things like biologics

43:34

and plasmapheresis

43:35

and all the things that we're trying to do.

43:37

I can't compete with the scalability of that.

43:41

But what I can compete with

43:42

and I can destroy is the quality.

43:45

Because if we provide quality care

43:47

and we make sure that we scale

43:49

at a level that is true

43:51

and holds integrity

43:53

to the patient relationship,

43:54

that's one of the biggest things I saw.

43:56

I even came on here

43:57

and there's things that I've gotten wrong.

43:58

I thought the fastest way to scale

44:00

and to meet the needs

44:01

of the American people is AI.

44:03

And I still believe that.

44:05

But where I got it wrong

44:07

and where I think the nuance is important

44:09

is I've had this epiphany,

44:12

AI is a tool.

44:13

But like all the other tools,

44:15

at the end of the day,

44:17

everything always starts with people.

44:19

Everything.

44:20

The entire human experience

44:22

doesn't exist without people.

44:24

So like there is never going to be

44:27

anything more meaningful to a person

44:30

than another human supporting them,

44:32

caring for them,

44:34

and being in their corner.

44:35

And that is the importance

44:36

of a clinician relationship.

44:38

And having clinicians

44:40

that are employees of an institution,

44:42

not hourly people

44:44

who are paid to hop on a call

44:45

and on a Monday they're pulling babies

44:48

and on a Tuesday

44:48

they're a testosterone expert.

44:50

That is what a lot

44:51

of these telemedicine companies are now.

44:53

And it may provide accessibility,

44:55

but is that optimal care?

44:57

Is that preventative care?

44:58

Or are we back to that same conundrum

45:00

of how do we make a quick buck?

45:02

How do we get this guy

45:03

on a bunch of peptides

45:04

or girl on a bunch of peptides

45:06

and we push him out the door?

45:07

And that is one of the challenges

45:08

of even this emerging market

45:10

is people are compromising pretty quickly.

45:13

And even this market,

45:15

I see the flaws.

45:17

And those flaws

45:18

are going to bring out the naysayers.

45:19

And those naysayers

45:20

are going to use the bad actors

45:22

and the bad examples

45:23

to crucify the industry.

45:24

And I'm banging the drum a lot

45:26

against HIMSS right now,

45:27

but I tried explaining this

45:29

to Secretary Kennedy

45:30

and the administration.

45:31

HIMSS did a Super Bowl ad

45:34

where they made claims

45:35

and they used the,

45:36

literally the GLP-1 brand name

45:39

of Novo Nordisk drug

45:41

and violated the law.

45:43

And I told the administration,

45:45

there is no way

45:47

that a multi-billion dollar conglomerate

45:49

would make this mistake.

45:51

This is the equivalent

45:53

to somebody coming

45:54

into your living room

45:55

and taking a dump

45:56

on your dining room table

45:57

and you assuming

45:58

that it was an accident.

45:59

How do they violate the law?

46:00

What do they do?

46:01

You're not allowed to,

46:02

so when you're compounding a medication,

46:04

you have to use

46:05

the compounded name,

46:07

the generic name,

46:08

not the molecule's name,

46:09

not the brand name.

46:10

So it'd be like saying,

46:11

we have Kleenex

46:13

for cheaper than Kleenex,

46:14

right?

46:15

and we have the exact same compound.

46:18

It's technically,

46:19

is it the same molecule in theory?

46:22

Yes.

46:22

But in marketing,

46:24

one,

46:25

you're not supposed to market

46:26

if you're compounding.

46:28

You're not supposed to market

46:29

direct to consumers

46:30

like Big Pharma does.

46:31

So there's a lot of like guidelines.

46:32

They spent the money,

46:33

they got the patent,

46:34

all of this.

46:34

The reason that's important

46:36

is that Trojan horse was set.

46:39

It created an extreme backlash

46:41

from regulators,

46:42

both senators,

46:44

congressmen,

46:45

congresswomen,

46:46

politicians

46:46

from all different walks of life

46:48

came out saying,

46:49

this is unacceptable.

46:50

All of these people

46:52

making black market peptides

46:54

and GLP-1s

46:56

and marketing direct

46:57

to our consumers

46:58

and violating patent laws

46:59

and infringing upon

47:00

these pharmaceutical companies.

47:02

All of that shakes out.

47:04

Statements made

47:05

by all these varying politicians

47:07

and then what happens

47:08

within a week?

47:09

HEMS inks a deal

47:10

with Novo Nordisk

47:11

to bring the pharmaceutical drug

47:14

to their practice

47:15

and have a sole source agreement.

47:17

So they set a landmine

47:19

in the middle of all compounders

47:21

and I'm trying to explain

47:22

to the administration,

47:22

you got to understand,

47:24

they're not a compounding,

47:25

they're a multi-billion dollar

47:26

marketing firm.

47:27

There's no way

47:28

this was an oversight

47:29

or a mistake.

47:30

This was by design

47:32

and then what happened

47:33

is the largest run

47:35

probably in the,

47:36

I don't know,

47:36

in the last decade

47:37

of any stock price,

47:38

HEMS is shot through the roof

47:41

because they inked the deal

47:42

with Novo

47:44

and said,

47:44

now we're going to provide you

47:45

with the brand name

47:47

of the drug

47:48

after they had set

47:49

this landmine off

47:50

in the middle

47:50

of all of these compounders.

47:52

And so the reason

47:53

that's important, Joe,

47:53

is there are bad actors

47:56

doing things

47:56

that I think are doing them

47:57

by design

47:58

to damage the industry

47:59

and to create

48:00

a battle cry

48:01

and a resistance

48:02

against the folks

48:04

who are trying

48:04

to follow the rules

48:05

and navigate

48:06

a very narrow pathway forward

48:08

where these peptides

48:11

and these treatment modalities

48:13

are available

48:14

to the public.

48:14

All the while,

48:15

while they have an agreement

48:17

with this pharmaceutical

48:18

drug company.

48:19

You got it.

48:20

The deal was done

48:21

within two weeks.

48:21

Oh, boy.

48:22

Backlash came.

48:23

A huge uproar

48:24

against...

48:25

And this is...

48:26

The reason this is so important

48:27

is I was literally

48:28

doing calls

48:29

with the administration

48:29

to go,

48:30

hey,

48:30

I get why Big Pharma

48:32

would be upset

48:33

and they should be.

48:34

And I get why you,

48:35

the administration,

48:36

would be upset

48:37

and you should be.

48:38

But please,

48:39

do not punish

48:40

an entire industry sector

48:42

for one bad actor.

48:44

And at the time,

48:45

I was scratching my head

48:46

going,

48:46

this just doesn't make sense.

48:47

Why would they do this?

48:48

They're going to get hammered.

48:50

They will not win this

48:51

in the court of law.

48:51

This is a terrible idea.

48:54

None of it's adding up.

48:55

And then a week later,

48:56

they make this announcement

48:58

and the stock roars.

49:00

And, you know,

49:01

everyone goes,

49:02

oh, congrats,

49:03

Hems.

49:03

And it's like,

49:04

no, this was...

49:05

And we'll find out

49:07

because there is a huge

49:09

class action lawsuit now,

49:10

an antitrust lawsuit

49:11

that's going on.

49:12

I think Lee Rosebush

49:14

and his firm

49:15

brought it forward.

49:15

He's a...

49:16

a guy who's

49:18

academically trained.

49:20

I think ran the clinic

49:22

at the Mayo Clinic,

49:23

ran the lab.

49:23

He's a pharmacist.

49:24

He's a law degree,

49:25

all these things.

49:26

And he's in this industry

49:28

and in this sector.

49:29

And he's asking

49:30

a lot of questions.

49:31

And I think his firm

49:32

filed a lawsuit

49:33

against Hems

49:33

to try and uncover

49:35

what really happened there.

49:36

But even if it does

49:37

get uncovered,

49:38

what's going to change?

49:39

No one's going to pay attention.

49:40

It'll, you know,

49:42

it'll be a blurb

49:43

in the news.

49:43

It won't even be in the news.

49:44

Yeah.

49:45

You know,

49:46

it'll be online somewhere.

49:47

Well, the main reason

49:47

I want to give that tidbit

49:48

of information

49:49

is regulators

49:51

and politicians

49:52

are looking and going,

49:53

God, man,

49:53

yeah, these guys

49:54

did bad things.

49:55

No, the guys

49:55

that were doing

49:56

the bad things

49:56

already inked

49:57

their backroom deal

49:58

and rode off

49:58

into the sunset.

49:59

So now what is left

50:01

for the rest of the industry

50:02

and where does this go?

50:03

And that's a slippery slope.

50:05

And again,

50:06

separate from peptides,

50:07

separate from compounds,

50:08

you get into the whole world

50:09

of biologics

50:10

and the future of biologics

50:13

and stem cells

50:14

and creating a regulatory pathway.

50:16

And again,

50:16

Secretary Kennedy,

50:17

he tweeted this,

50:18

I think before

50:19

or right when he took over,

50:20

save your records

50:21

and pack your bags.

50:22

Your war on stem cells

50:23

and peptides are over.

50:24

And I can tell you

50:27

from my meetings now

50:28

further down the line

50:29

with the FDA,

50:30

I have just a more,

50:32

I mean,

50:33

I hate to concede,

50:34

but I have a more

50:35

nuanced lens on

50:36

they're trying to navigate

50:39

an absolute nightmare

50:41

of regulatory landscape,

50:43

of, you know,

50:45

the lobbying power,

50:46

the impression,

50:47

the half-baked truths,

50:49

where does the truth lie?

50:51

Well, this is how

50:51

this entire system's built.

50:53

Well, this is what we know.

50:54

Well, we don't really know

50:55

cash pay.

50:56

Well, we don't really,

50:57

right?

50:57

The whole model is

50:59

get a drug approved,

51:00

it costs billions of dollars.

51:01

Now we've got to lock

51:02

in that patent.

51:03

Now we've got to let

51:04

these companies make

51:05

a bunch of money on it

51:06

because they innovated it

51:07

and we've got to

51:09

get it on insurance

51:10

formularies,

51:10

Medicare, Medicaid,

51:11

and TRICARE.

51:12

That's a whole fundamental

51:14

difference when you're

51:14

talking about even,

51:15

like, let's shelf

51:16

peptides for a second,

51:17

say stem cell therapy.

51:18

My whole mission statement

51:21

on all of this is

51:22

to build a life raft,

51:23

right?

51:24

Henry Ford said

51:25

if we would have asked,

51:26

if he would have asked

51:27

clients what they wanted,

51:28

they would have said

51:28

a faster horse,

51:29

right?

51:30

I'm not going to the FDA

51:31

going, guys,

51:32

how do we solve this problem?

51:33

I think the FDA

51:34

has enough of their own problems

51:36

just trying to manage

51:37

the system the way it is.

51:38

My vision is

51:39

you build a life raft.

51:40

You build a life raft

51:42

parallel to the existence,

51:43

much like Uber did

51:44

with taxis.

51:45

And you let this go this way

51:46

and you dry drag race

51:48

it against this way

51:49

and let's see

51:50

who can prevent

51:51

chronic disease.

51:52

Well, the problem is

51:53

it killed taxis.

51:54

Yeah.

51:55

That was a bad example.

51:56

Well, I think

51:57

the question is

51:59

which model

52:00

is going to be better

52:00

for humanity

52:01

and which model

52:02

is going to take cost

52:03

out of the system?

52:03

Right.

52:04

And so I would tell

52:05

a regulator,

52:05

a congressman,

52:06

a congresswoman,

52:07

anybody who will listen,

52:08

guys, my model

52:09

costs you nothing.

52:10

I'm not asking

52:12

for taxpayer dollars.

52:13

I'm not asking

52:14

for any sort of indication

52:16

where I can bill

52:17

insurance companies

52:18

or I can bill

52:18

Medicare, Medicaid,

52:19

or Tricare.

52:20

What I'm asking

52:21

the federal government

52:22

to do is to trust

52:23

the sacred relationship

52:24

of a clinician

52:25

and a patient

52:26

and to allow a patient

52:27

to have sovereignty

52:29

and autonomy

52:29

over their health.

52:30

If I'm Brett Favre

52:32

and I'm diagnosed

52:33

with an advanced stage

52:35

of Parkinson's disease

52:36

and it's a kiss of death,

52:38

why would I want

52:40

to wait 10 years

52:41

for something to make it

52:42

through the FDA approval process

52:44

that could change

52:45

or save my life today?

52:46

And if I have the means

52:49

to pay for those things

52:50

and the accessibility

52:51

in a clinician

52:52

who thinks that

52:53

they have an answer

52:54

to slow

52:55

or help potentially

52:57

improve the progression

52:59

of a chronic disease

53:00

or an ailment,

53:01

I just don't think

53:02

the government

53:03

should stand in the way

53:04

of that.

53:04

And the reality

53:05

is that the momentum

53:06

of the current

53:07

healthcare system

53:08

is so strong

53:09

that the vast majority

53:10

of Americans

53:11

are going to use

53:11

that anyway.

53:12

It's not like

53:14

it's going to

53:14

completely disrupt

53:15

the system.

53:17

like most people

53:19

like, I mean,

53:20

how many people

53:20

are listening to this?

53:21

You know, I mean,

53:22

it's still a small

53:23

percentage of just America.

53:25

Yeah.

53:25

The vast majority

53:27

of people are just

53:28

going to trust

53:28

their doctor

53:29

and they're going

53:29

to do what

53:30

they've always done.

53:31

They're not going

53:32

to be aware

53:32

and it's going

53:33

to be business

53:34

as usual

53:34

and those companies

53:35

are still going

53:36

to grow.

53:36

Yeah.

53:37

It's just,

53:37

they're so greedy.

53:38

They want all of it.

53:39

Yeah.

53:40

Like by saying

53:40

they're losing

53:41

$7 billion,

53:42

how much did you make?

53:43

This episode

53:45

is brought to you

53:45

by Athletic Brewing.

53:47

Athletic Brewing Company's

53:48

non-alcoholic beer

53:50

is a total game changer.

53:51

The first time you try it,

53:52

you're like,

53:53

wait,

53:53

how is this non-alcoholic?

53:55

They've won

53:56

185 Global Taste Awards

53:59

and they've got

54:00

a ton of different styles.

54:01

You get the ritual,

54:02

you still get the taste,

54:04

just without the hangover.

54:05

They've got everything,

54:06

Goldens,

54:07

IPAs,

54:08

Light Brews,

54:09

even this new

54:10

Lime and Salt one

54:11

if you want

54:12

something refreshing.

54:13

Whatever the mood calls for,

54:14

they've got the flavor.

54:15

You can find

54:16

Athletic Brewing

54:17

at over 75,000

54:20

grocery stores

54:21

or liquor stores,

54:22

bars and restaurants

54:23

nationwide,

54:24

or you can grab

54:26

some of their

54:26

limited release stuff

54:27

directly from their website.

54:29

Go to

54:29

athleticbrewing.com

54:31

slash rogan

54:32

to find stores

54:33

near you

54:34

or get brews

54:35

shipped

54:36

right to your door.

54:37

Use code rogan

54:39

to get 15% off

54:40

your first online order.

54:42

near beer.

54:43

Terms and condition

54:45

and certain limitations

54:46

apply.

54:47

Athletic Brewing Company

54:48

fit for all times.

54:50

You know what I mean?

54:51

Well, that was my point.

54:52

Right, they're not losing

54:53

any money.

54:54

If you give those

54:55

bad facts

54:56

to a politician

54:57

or a regulator,

54:58

they go,

54:58

oh my God.

54:59

They cost you

55:00

$7 billion.

55:00

You made $800 billion.

55:03

Your market cap

55:05

is eight.

55:05

You 7xed your company.

55:07

Novo Nordisk

55:08

3 or 4xed their company

55:10

in literally

55:11

a three-year time frame.

55:12

These are some

55:13

of the most rich

55:14

and powerful companies

55:15

in the world.

55:16

Your patent worked.

55:18

It worked.

55:19

It upheld.

55:19

You prevented

55:20

regulatory landscape

55:22

from coming in

55:23

and people

55:23

taking a piece

55:24

of your pie.

55:25

In fact,

55:26

I would argue

55:27

it worked too well.

55:28

You know,

55:28

in a way,

55:29

like,

55:30

so to over-regulate

55:32

based off,

55:33

and that's the argument

55:35

with the GLP-1s

55:36

in one bucket.

55:36

My argument,

55:37

you know,

55:38

for allowing compounders

55:40

to continue

55:40

to make these

55:41

patient-specific

55:42

are you need

55:43

to allow patients

55:44

to be able

55:44

to titrate up

55:45

and titrate down

55:46

and avoid

55:46

catastrophic muscle wasting.

55:48

What about patients

55:49

who have allergies?

55:50

What about the next time

55:51

these things go on

55:52

a backlog?

55:52

What about a patient

55:54

who maybe can't

55:56

handle the

55:58

delivery mechanism?

56:01

I mean,

56:01

there's dozens

56:02

of different reasons

56:03

why you would want

56:04

to provide

56:05

an alternative life raft.

56:06

Can you explain

56:08

the titrate up

56:08

and titrate down thing?

56:09

Yeah,

56:10

so historically,

56:11

the GLP-1s

56:13

came in preset dosages.

56:14

Right.

56:15

And so patients

56:16

did not have a way

56:17

to titrate up

56:19

or down,

56:20

and so a lot

56:20

of clinicians

56:21

who wanted to microdose

56:22

would use a compounding pharmacy

56:24

to prescribe

56:25

those medications

56:25

and allow patients

56:27

more flexibility

56:28

on how they dose

56:30

their GLP-1.

56:31

Because some of the

56:31

catastrophic side effects

56:33

come from a large dose.

56:34

Correct.

56:34

Now,

56:36

as this thing evolves,

56:38

the question becomes

56:39

where do we go

56:40

with this, right?

56:41

Because essentially,

56:43

most compounding

56:44

has shut down

56:45

GLP-1s,

56:46

503Bs,

56:47

which B stands for bulk,

56:49

like big mass production.

56:51

I can sell big bulk items

56:52

to hospitals

56:53

or to clinics.

56:54

The government's come in

56:55

and said they're not

56:56

allowed to make

56:56

the weight loss drugs anymore.

56:57

So it's now limited

56:59

down to just 503As,

57:01

which are patient-specific,

57:02

which is like what I do.

57:04

Like we make medications

57:05

unique to the patient,

57:06

personalized medicine.

57:07

And so that's a much

57:10

more niche

57:10

percentage of the market.

57:12

And again,

57:14

even that,

57:14

you're talking

57:15

in the heyday,

57:15

maybe $2 billion

57:17

for the whole industry,

57:19

on a company

57:22

that's worth

57:24

$800 billion

57:25

and 7X their revenue,

57:26

everything's going

57:28

to be okay.

57:28

Like everyone's

57:29

going to be okay.

57:30

Patients had accessibility

57:31

and affordability.

57:32

And I think

57:34

the battle cry

57:35

from the big

57:37

pharmaceutical companies

57:37

is a little misleading

57:39

if you don't know

57:40

the nuances

57:41

of all of this.

57:42

So what do you think

57:46

is the best way forward

57:48

if you were in charge

57:51

of regulating?

57:53

There is an issue

57:55

with accessibility

57:56

and there's an issue

57:57

with black market.

57:59

Correct.

57:59

Right?

57:59

There's an issue

58:00

with people buying peptides online

58:02

that are not even

58:03

what they say they are.

58:04

Like there's certain peptides

58:06

that have a physiological response

58:07

when you take them,

58:08

like CJC ipamoralin.

58:10

You can feel it

58:11

when you take it.

58:12

I know people

58:13

that have bought stuff online

58:14

and they say,

58:15

I don't think this stuff

58:15

is legit

58:16

because it's not doing anything

58:17

once I take it.

58:18

I don't feel that,

58:19

you know,

58:19

that weird flushing response?

58:20

They don't feel it at all.

58:22

And they've asked me

58:24

for advice.

58:24

No, I love that you had,

58:26

because I actually

58:27

had the privilege

58:28

of giving this,

58:30

you know,

58:30

message to Marty McCary

58:32

at the FDA

58:33

and also Chris Klump

58:36

who have been receptive

58:37

to at least hearing

58:38

the other side

58:38

of the equation.

58:39

And to be clear,

58:41

when it comes to peptides,

58:42

Chris,

58:43

Marty,

58:43

Stephanie,

58:45

Spear,

58:47

Bobby,

58:48

all of them are aligned.

58:49

Like peptides,

58:50

I'm being told are done.

58:51

It's just a matter of when.

58:52

I don't have that timeline,

58:54

but it's a huge win

58:56

because it goes so much bigger.

58:59

I cannot stress Joe

59:01

how close

59:02

preventative longevity-based medicine

59:05

was to being done.

59:06

Because if you shut down

59:08

all compounders

59:09

throughout the country

59:10

and they've already gone

59:11

after the black and gray market,

59:13

the FBI has shown up

59:14

at these people's doors.

59:15

And if Kennedy

59:16

wasn't the secretary

59:17

and if the Maha movement

59:20

hadn't started,

59:20

it's over.

59:21

It's over.

59:22

It's over.

59:22

So if Kamala Harris wins,

59:25

it's over.

59:26

Yeah.

59:26

And on that note,

59:28

even here in Texas,

59:29

this is where this is crazy.

59:31

I've gotten to know

59:33

several of the congressmen,

59:34

congresswomen.

59:35

Lacey Holes,

59:36

a congresswoman here in Texas.

59:37

Senator Coalhurst,

59:39

I believe she's over

59:40

the health care committee

59:41

for the Senate.

59:42

Senator Coalhurst

59:43

was looking at

59:44

forming her own FDA

59:45

for Texas.

59:46

That's how serious

59:47

that was getting

59:48

because they knew

59:49

that of everything

59:51

that's happened,

59:51

where this would continue

59:52

to head,

59:53

and states were looking

59:54

to potentially hedge

59:56

their bet

59:56

to protect

59:57

their state citizens

59:59

from the federal guidelines

1:00:00

that could be

1:00:02

restrictive

1:00:02

or preventative

1:00:03

for care,

1:00:04

which is crazy to think.

1:00:06

So when I laid this out

1:00:08

for Marty,

1:00:12

one of the things

1:00:13

I explained were

1:00:14

here's what the naysayers

1:00:16

will say.

1:00:17

We don't want it

1:00:18

to be the Wild West.

1:00:19

You're going to

1:00:20

grandfather in peptides

1:00:21

and give people

1:00:22

accessibility to peptides

1:00:23

and that would be

1:00:24

the Wild West.

1:00:25

And my answer to that

1:00:25

is we are living

1:00:27

in the Wild West.

1:00:28

Today is the most

1:00:29

dangerous time

1:00:30

it has ever been

1:00:31

in the history of peptides.

1:00:33

Peptides have grown legs,

1:00:35

the cat's out of the bag,

1:00:37

everyone knows

1:00:38

what they were,

1:00:38

they got a taste

1:00:39

of the efficacy

1:00:40

and the benefits,

1:00:41

and patients aren't

1:00:42

going to stop using them.

1:00:44

So right now,

1:00:44

four out of five peptides

1:00:46

being filled

1:00:47

are being filled

1:00:48

through gray

1:00:48

or black market solutions.

1:00:50

When Eli Lilly

1:00:51

and Novo

1:00:52

throw out

1:00:52

a $7 billion number

1:00:54

where they're cooking

1:00:55

the books

1:00:56

is they're not

1:00:57

telling legislators

1:00:58

that a lot of that

1:00:59

is gray and black market.

1:01:00

Four out of five.

1:01:01

Meaning there is

1:01:03

no clinician

1:01:03

in the chain of custody.

1:01:05

The majority.

1:01:06

The majority.

1:01:07

Four out of five.

1:01:08

This cookbook

1:01:08

$7 billion

1:01:09

is black market.

1:01:11

Correct.

1:01:11

And again,

1:01:12

even in the black market.

1:01:14

And many of them

1:01:14

aren't even real.

1:01:15

Yes.

1:01:16

And I want to be clear.

1:01:17

I'm not,

1:01:17

even in the black market,

1:01:19

I know,

1:01:20

and I've validation tested

1:01:22

and done independent

1:01:23

validation testing

1:01:24

of a lot of these companies.

1:01:25

And some of them

1:01:27

are efficacious.

1:01:28

Some of them are real.

1:01:29

And some of them

1:01:30

are not.

1:01:30

What is the percentage?

1:01:31

Roughly.

1:01:32

A large percentage

1:01:34

is off

1:01:35

like in sometimes

1:01:36

dosed higher,

1:01:37

you know,

1:01:38

so think about

1:01:38

if you were to get

1:01:39

like a GLP-1

1:01:40

and you're injecting

1:01:41

a dosage that's 2x

1:01:43

what it should be,

1:01:45

right?

1:01:45

You could have muscle wasting

1:01:47

or all sorts

1:01:47

of catastrophic events.

1:01:49

And this is just

1:01:49

because of a lack

1:01:50

of regulation.

1:01:50

Correct.

1:01:51

There's no regulation.

1:01:51

There's no regulation.

1:01:52

There's no oversight.

1:01:53

And these companies

1:01:55

attempt to operate

1:01:56

through a loophole

1:01:57

and that loophole

1:01:57

is they claim

1:01:58

it's for non-human use.

1:01:59

I actually had a call

1:02:02

with a really prominent

1:02:03

peptide company

1:02:04

and their CEO

1:02:05

who's an Ivy League guy

1:02:06

and I get on the phone

1:02:07

with this guy

1:02:08

and he's wanting

1:02:09

to huff and puff

1:02:10

and tell me

1:02:11

how I don't know

1:02:11

what I'm talking about

1:02:12

and that he's safe

1:02:13

and that he has

1:02:14

written legal opinions

1:02:15

and that he knows

1:02:16

what he's allowed to do

1:02:17

and not allowed to do.

1:02:18

And I said,

1:02:19

well,

1:02:19

I can tell you

1:02:20

from history

1:02:21

what I've seen.

1:02:22

You are using influencers

1:02:24

to advertise

1:02:25

for human use.

1:02:26

You say on your label

1:02:28

non-human use.

1:02:29

But the second

1:02:31

somebody has

1:02:32

this event

1:02:32

and has something

1:02:34

catastrophic happen,

1:02:35

ODs or dies,

1:02:36

the DOJ is going

1:02:38

to show up

1:02:38

on your door

1:02:39

and when they do,

1:02:40

they're going to subpoena you

1:02:41

and when they do,

1:02:43

they're going to uncover

1:02:44

that you were paying

1:02:45

influencers

1:02:46

to advertise

1:02:47

these products

1:02:48

for human use

1:02:49

while putting on the label

1:02:50

they're for non-human use.

1:02:51

So you are knowingly

1:02:53

and willingly

1:02:53

circumventing

1:02:55

the safety

1:02:55

and the laws

1:02:57

of the land

1:02:58

to push

1:02:59

a legal compound

1:03:00

into a marketplace.

1:03:02

I'm just telling you

1:03:03

how this is going

1:03:03

to play out.

1:03:04

I'm not hoping

1:03:05

this for anybody.

1:03:06

And this was about

1:03:07

eight months ago

1:03:08

and now it's happened.

1:03:09

Now the FBI

1:03:10

has shown up

1:03:11

at multiple

1:03:12

gray and black

1:03:12

market peptide facilities.

1:03:13

If we're being honest,

1:03:15

it's 100%

1:03:16

because of Red or True Tide,

1:03:17

the next blockbuster

1:03:18

GLP-1

1:03:19

that is in the works.

1:03:21

Can you explain that?

1:03:23

Yeah.

1:03:23

So Red or True Tide

1:03:25

is a triple agonist

1:03:26

being developed

1:03:27

by Eli Lilly

1:03:28

and so it hits

1:03:28

three different

1:03:29

receptor sites.

1:03:30

It has less

1:03:31

muscle wasting,

1:03:32

much better

1:03:34

safety profile,

1:03:35

lower side effect profile,

1:03:37

but people drop

1:03:38

substantial amounts

1:03:39

of body fat.

1:03:40

And that drug

1:03:40

is not on the market.

1:03:41

It has not made it

1:03:42

through phase three trials.

1:03:43

It's not

1:03:45

commercially available.

1:03:47

So we got a letter

1:03:49

as a compounding pharmacy

1:03:50

under the FDA guidelines

1:03:52

telling us

1:03:53

it is illegal

1:03:54

if you make this

1:03:55

and we will come after you.

1:03:56

So we've never made it

1:03:57

because we're a compounding pharmacy

1:03:59

that has to follow

1:04:00

the laws of the land

1:04:01

because the state

1:04:02

and the federal government

1:04:03

inspect us.

1:04:04

Right before we came on,

1:04:05

I was telling you,

1:04:06

the FDA has been

1:04:07

in our building

1:04:08

five times in four years.

1:04:10

The states have been

1:04:12

in my building every year

1:04:13

and I'm in 47 states.

1:04:15

So almost every state

1:04:16

we're literally

1:04:17

in an inspection

1:04:18

all the time.

1:04:19

There are plenty

1:04:21

of safety nets.

1:04:22

We independently,

1:04:22

third-party verify

1:04:23

every dosage.

1:04:24

We buy API

1:04:25

from what's called

1:04:26

the green list.

1:04:27

The green list

1:04:28

is a list established

1:04:29

by the FDA

1:04:29

that tells us

1:04:30

you can buy

1:04:31

these pharmaceutical ingredients

1:04:33

from these ingredient manufacturers.

1:04:36

What does API stand for?

1:04:37

It's pharmaceutical ingredients.

1:04:39

It's just the base product

1:04:40

used to compound

1:04:41

a medication.

1:04:42

None of those

1:04:44

checks and balances

1:04:45

happen in the gray

1:04:46

and black market.

1:04:47

Again,

1:04:47

it's not saying

1:04:48

that all those guys

1:04:49

are bad

1:04:49

or that their product's bad.

1:04:51

But regardless,

1:04:53

whether...

1:04:53

They're not regulated.

1:04:54

100%.

1:04:55

There's no regulation.

1:04:56

There's no checks

1:04:57

and balances.

1:04:57

So if I'm...

1:04:58

It very least

1:04:58

leaves the door open.

1:05:00

Correct.

1:05:00

It leaves the door open

1:05:01

and if I am a patient

1:05:04

who wants to get

1:05:05

on a weight loss drug

1:05:06

and I can just buy it online

1:05:07

and not have to go to a doctor

1:05:09

and not have to go to a clinic

1:05:11

and get blood work

1:05:12

and I can just buy it,

1:05:13

there's no doctor,

1:05:14

there's no pharmacist,

1:05:15

it's drop shipped to my house.

1:05:16

What's even scarier though

1:05:18

is there's no dosing instructions.

1:05:20

There's no way

1:05:21

to reconstitute it.

1:05:22

There's no explanation

1:05:23

of how to reconstitute

1:05:24

because once they're teaching you

1:05:26

how to reconstitute

1:05:27

and mix it,

1:05:28

they're taking part

1:05:29

in medical administration

1:05:30

and so these companies

1:05:32

have avoided all of that

1:05:33

and people were using

1:05:34

things like ChatGPT

1:05:36

but now ChatGPT

1:05:37

and all the large language models

1:05:39

have shut that down.

1:05:39

So now what you have

1:05:41

is American people

1:05:42

buying random product

1:05:44

online with no guidance,

1:05:46

no oversight,

1:05:46

no clinician

1:05:47

in the chain of custody,

1:05:48

no checks and balances,

1:05:50

no state or federal regulators.

1:05:52

We are living in the Wild West.

1:05:54

So my message to Marty

1:05:56

and if you want to fix this,

1:05:58

how you fix it

1:05:58

is you bring back

1:05:59

where we were

1:06:01

prior to the mistake

1:06:02

of the Biden administration

1:06:03

where they pulled

1:06:05

these peptides

1:06:05

from the market

1:06:06

with no safety data

1:06:09

that can support

1:06:10

their actions

1:06:11

and you put it back

1:06:13

in the hands

1:06:14

of trained clinicians.

1:06:15

You require people

1:06:16

to go through

1:06:17

the process

1:06:18

where they have

1:06:19

a clinician

1:06:20

and a pharmacist

1:06:21

and a compounding pharmacy

1:06:22

under the right guidelines

1:06:24

regulating the space

1:06:25

because we know

1:06:27

no peptides are safe.

1:06:28

Like they are safe.

1:06:30

They're 200 peptides

1:06:32

are found naturally

1:06:32

occurring in the human body.

1:06:34

These are raw elements

1:06:36

that are readily available

1:06:37

in nature.

1:06:38

The question is

1:06:39

sterility,

1:06:40

efficacy,

1:06:41

and safety.

1:06:43

And through the proper

1:06:44

checks and balances,

1:06:45

we can minimize

1:06:46

most of those

1:06:47

side effect profiles

1:06:48

and optimize

1:06:49

positive outcomes.

1:06:50

but it requires

1:06:52

restoring law

1:06:54

and order to the land

1:06:55

and implementing things

1:06:56

the way they were

1:06:57

before the mistake happened.

1:06:59

And that's all

1:07:00

I've been trying to argue.

1:07:01

There's a way to fix this

1:07:02

and if you do that

1:07:03

overnight,

1:07:05

as much as I hate

1:07:06

to say this,

1:07:07

you make these big

1:07:08

pharmaceutical companies

1:07:09

ecstatic

1:07:10

because you just got rid

1:07:12

of four out of five

1:07:13

weight loss drugs

1:07:14

that were being filled

1:07:14

with no clinician

1:07:15

and you do push it

1:07:17

in a way back

1:07:18

to the traditional system

1:07:20

with the checks and balances

1:07:21

that these regulatory bodies

1:07:24

are so worried about.

1:07:25

And the only argument

1:07:26

against that is,

1:07:27

well,

1:07:28

peptides don't have

1:07:30

enough robust

1:07:31

human clinical trials

1:07:33

with safety data.

1:07:34

And then you go down

1:07:36

that topic

1:07:36

and I'm like,

1:07:37

guys,

1:07:37

you do realize,

1:07:38

like we said,

1:07:39

like 60 to 80% of drugs

1:07:41

have a major label change.

1:07:42

These are the drugs

1:07:43

that make it through.

1:07:43

Separate from that,

1:07:44

every product

1:07:45

that's in the operating room,

1:07:46

I've covered this

1:07:47

every time I've been on here,

1:07:48

every single 90%

1:07:50

of the products

1:07:51

in the operating room

1:07:52

never had a human safety study.

1:07:53

They were all brought in

1:07:55

through the 510 approval process.

1:07:57

Doctors are using things

1:07:59

every day in practice

1:08:01

that are either off-label

1:08:02

or not validation tested

1:08:05

or have no human safety studies.

1:08:07

It is commonplace

1:08:08

in medicine every day.

1:08:10

So to make it

1:08:11

this big to-do

1:08:12

that all of a sudden

1:08:14

it's dangerous

1:08:15

the most dangerous time

1:08:17

we're living in

1:08:17

is right now

1:08:18

with no checks and balances.

1:08:19

If we get this done,

1:08:20

you've now built

1:08:21

a regulatory pathway

1:08:23

that provides affordability,

1:08:25

accessibility,

1:08:26

personalized medicine,

1:08:27

predictive care.

1:08:28

It is such a big win

1:08:30

beyond a peptide

1:08:32

because it candidly

1:08:33

saves the industry.

1:08:34

I can tell you,

1:08:35

owning clinic,

1:08:36

owning a telemedicine company,

1:08:38

owning all of these things,

1:08:39

none of that machine works

1:08:41

if we can't create products

1:08:43

if we can't create products

1:08:43

that help people.

1:08:44

Right?

1:08:45

And so,

1:08:46

quality,

1:08:48

products that are available

1:08:50

without quality

1:08:51

are even worse

1:08:52

than quality products

1:08:54

that aren't available.

1:08:54

You know,

1:08:55

and those were our two options

1:08:57

right now.

1:08:57

It's like,

1:08:58

they can't get a quality product

1:08:59

and then we can't sell

1:09:01

the quality product.

1:09:02

But this change

1:09:03

will allow us

1:09:04

to sell safe

1:09:05

and quality products

1:09:08

with the proper checks

1:09:10

and balances.

1:09:11

And it also builds

1:09:12

a regulatory pathway

1:09:13

that I think

1:09:14

sets us up

1:09:14

for long-term success

1:09:15

with things like stem cells.

1:09:17

Well,

1:09:17

it seems like

1:09:17

such a reasonable concession.

1:09:19

You cut out the black market,

1:09:20

you regulate stem cells

1:09:23

and you regulate peptides,

1:09:24

you regulate everything

1:09:26

that's being done

1:09:26

through compound pharmacies.

1:09:27

Everybody wins.

1:09:29

I agree.

1:09:30

That's the message

1:09:31

that I've had.

1:09:32

I don't think

1:09:33

the pharmaceutical drug companies

1:09:34

want everybody to win.

1:09:35

Correct.

1:09:35

They want only them to win.

1:09:37

Correct.

1:09:38

So any profit

1:09:39

that you make

1:09:40

or any compounding pharmacy makes

1:09:42

in their mind

1:09:43

is stolen from them.

1:09:44

Correct.

1:09:45

Which is wild.

1:09:46

Yeah.

1:09:47

And that is the big challenge

1:09:49

is the future

1:09:50

of this regulatory pathway

1:09:51

and that's where

1:09:52

I wanted to get into the state.

1:09:53

And this is something

1:09:54

that what we saw

1:09:56

with the food lobby,

1:09:58

when we testified

1:09:59

at the state level

1:10:00

for the food program,

1:10:02

for the SNAP program,

1:10:03

for the school lunch program,

1:10:04

trying to align

1:10:06

the state

1:10:07

with the new goal

1:10:09

of the food pyramid

1:10:11

and the new food guidelines

1:10:12

and get back

1:10:13

to eating real food,

1:10:14

healthy food,

1:10:15

instead of feeding kids

1:10:16

crap all day in school,

1:10:17

the states picked up

1:10:19

the torch

1:10:20

and ran with it

1:10:20

faster than the federal

1:10:21

government did.

1:10:22

And the reason

1:10:23

that's important

1:10:24

is we've now learned

1:10:25

the offense.

1:10:26

Texas passed the bills,

1:10:28

three different bills

1:10:28

around food

1:10:29

and food initiatives

1:10:30

and label changes

1:10:31

and protecting children.

1:10:33

Arizona followed suit.

1:10:35

I think Florida

1:10:36

multiple states

1:10:37

followed suit,

1:10:38

which creates

1:10:39

a trade win

1:10:40

that allows

1:10:40

the federal government

1:10:41

to pick up

1:10:42

what state legislators

1:10:43

have done

1:10:44

and mirror those bills.

1:10:45

So I say that

1:10:46

because I am already

1:10:48

working at the state level

1:10:49

to do the same thing

1:10:51

here in Texas.

1:10:51

So my hope is

1:10:52

that the federal government

1:10:54

and the FDA

1:10:55

get this done

1:10:57

with peptides

1:10:58

and then the next step

1:10:59

would be

1:10:59

can we do the same thing

1:11:00

with biologics

1:11:01

and stem cells,

1:11:01

which are amazing tools

1:11:02

in the tool belt

1:11:03

to drive health span

1:11:04

and help prevent

1:11:05

chronic disease.

1:11:06

The state of Texas

1:11:07

is already raring to go.

1:11:09

So the state of Texas

1:11:10

passed the Compassionate Use Act,

1:11:13

which says

1:11:14

if you have a chronic disease

1:11:15

or any sort of

1:11:17

chronic health issue,

1:11:18

you have the right to try.

1:11:20

So the reason

1:11:23

it's almost like marijuana law

1:11:24

without getting too nuanced.

1:11:25

The states,

1:11:27

if you have a clinic

1:11:28

within the state

1:11:28

and you manufacture

1:11:29

the product within the state

1:11:31

or compound within the state,

1:11:32

in theory,

1:11:33

you can administer

1:11:34

within the state.

1:11:34

And even if the FDA

1:11:37

has a different stance on it,

1:11:38

the state

1:11:39

can have its guidelines

1:11:42

and you can fall

1:11:42

within the rules

1:11:43

and regulations

1:11:44

of the state

1:11:44

and still honor

1:11:46

and respect

1:11:47

the rules of the land.

1:11:48

Does that make sense?

1:11:49

Yes.

1:11:49

Okay.

1:11:50

So Texas did this.

1:11:51

Utah did this.

1:11:53

Florida did this.

1:11:55

And I just testified

1:11:56

in Arizona two weeks ago

1:11:58

on the stem cell bill

1:11:59

in Arizona.

1:11:59

Senator Janae Champ

1:12:02

called me and said,

1:12:03

can you come out

1:12:03

and help testify

1:12:04

and can we do

1:12:06

what you guys have done

1:12:07

in Florida

1:12:07

and some of these other states?

1:12:08

states and right now

1:12:11

it passed through the House

1:12:12

and it's on to the Senate

1:12:14

and the Senate

1:12:14

will most likely

1:12:15

pass this bill.

1:12:16

And so I say all that

1:12:17

to go,

1:12:18

the states right now

1:12:19

are able to move faster

1:12:21

and more nimble

1:12:22

than the federal government

1:12:23

and the states

1:12:24

are building safety nets

1:12:26

and checks and balances

1:12:27

that will still allow

1:12:29

patient accessibility

1:12:30

at the state level.

1:12:32

The problem then becomes

1:12:33

if we can get

1:12:34

the federal government

1:12:35

to follow these same guidelines

1:12:37

and we've also submitted

1:12:38

a citizen's petition

1:12:41

to the FDA

1:12:42

around stem cells

1:12:43

that basically mirrors

1:12:45

the Florida law.

1:12:45

And the whole message

1:12:46

is exactly what you

1:12:47

and I have just covered.

1:12:48

Guys,

1:12:49

these things are safe.

1:12:50

The risk of an adverse event

1:12:52

is minimal.

1:12:53

If it is an adverse event,

1:12:55

it's flu-like symptoms

1:12:56

and it impacts basically

1:12:58

10 to 15% of people.

1:13:00

All of the major adverse events

1:13:02

you've been told

1:13:03

about stem cells

1:13:03

come from

1:13:04

improper chain of command,

1:13:06

improper chain of custody,

1:13:08

and improper checks and balances.

1:13:09

How do you fix that?

1:13:11

You fix that

1:13:12

through creating

1:13:13

a regulatory pathway

1:13:14

with proper

1:13:15

checks and balances,

1:13:17

proper chain of custody,

1:13:19

and a clinician involved

1:13:21

in the chain of command.

1:13:21

If we do those things,

1:13:23

you are going to be able

1:13:25

to provide patients

1:13:26

with affordable,

1:13:26

accessible care

1:13:27

of products that work

1:13:29

that are safe

1:13:30

while the federal government

1:13:32

can work through

1:13:33

do we make this

1:13:34

a billable product

1:13:35

down the road?

1:13:36

Do we build this

1:13:36

into the insurance model?

1:13:38

For me to go fight

1:13:40

to build this

1:13:40

into the insurance model

1:13:41

is a monumental task

1:13:43

that I don't have

1:13:44

the bandwidth to take on.

1:13:45

And I also think

1:13:47

it's the wrong move.

1:13:48

I really don't.

1:13:49

I don't want to be

1:13:49

part of that model.

1:13:50

I want to build a life raft

1:13:51

that allows patients

1:13:53

to make decisions.

1:13:54

And the second you put

1:13:55

this in an insurance model

1:13:56

or a government payer model,

1:13:57

everybody is castrated.

1:14:00

The decisions are made

1:14:01

at the insurance level

1:14:02

and at the government level,

1:14:04

and it just becomes

1:14:05

this nuanced,

1:14:06

challenging thing.

1:14:08

Like an example is

1:14:10

stem cells historically,

1:14:12

one of the uses

1:14:13

for purified amnion

1:14:14

was burn victims, right?

1:14:16

Or wound management

1:14:17

in diabetics.

1:14:18

So what happened?

1:14:19

Orthopedic surgeons

1:14:20

started billing

1:14:20

wound injuries

1:14:22

in order to get paid

1:14:24

from the insurance companies

1:14:25

on an ACL.

1:14:26

Well, that only takes

1:14:27

a year or six months

1:14:28

before the insurance companies

1:14:30

ring the bell

1:14:30

and go,

1:14:30

wait a second, dude.

1:14:31

This person billed us

1:14:32

a million dollars

1:14:33

on wound management

1:14:35

and they're an orthopedic surgeon.

1:14:36

What is going on?

1:14:37

Right?

1:14:37

You just committed

1:14:38

insurance fraud.

1:14:39

And now you've created

1:14:40

this counterculture movement

1:14:41

against stem cells

1:14:43

and purified amnion

1:14:44

and all of these products.

1:14:45

And that's what happened

1:14:46

in real time.

1:14:47

So a lot of what we're living

1:14:49

is the continual dogma

1:14:52

of this broken ass system.

1:14:54

And it creates this trade wind

1:14:56

that doesn't die.

1:14:57

I mean, this was a decade ago.

1:14:59

And now none of this stuff

1:15:01

is covered from insurance.

1:15:02

None of it has an FDA indication.

1:15:04

And all of it's kind of put

1:15:06

in this gray no man's land,

1:15:07

even though it's used

1:15:09

in practices every day

1:15:10

throughout the country.

1:15:11

And now you can legally

1:15:13

use these treatments

1:15:14

in states like Texas, Florida,

1:15:16

Arizona, soon to be Arizona

1:15:18

and Utah.

1:15:19

And so there is hope

1:15:21

because at the state level

1:15:22

it's moving.

1:15:22

I do believe Secretary Kennedy

1:15:24

and Chris Klump and Marty

1:15:26

are very open minded

1:15:27

and receptive to this.

1:15:28

They are very progressive

1:15:30

and they do see

1:15:32

the challenges of this system.

1:15:33

Marty covers it in his book,

1:15:34

like I said.

1:15:35

So I'm more optimistic

1:15:37

than ever that we are going

1:15:39

to get, if we get peptides done,

1:15:41

the next step

1:15:41

is to begin to work

1:15:43

the citizen's petition

1:15:45

to see if we can do

1:15:45

the same thing

1:15:46

for these biologics

1:15:47

and make these things

1:15:49

affordable and accessible

1:15:50

for everybody.

1:15:51

And the thing

1:15:52

that's helping them

1:15:53

momentum, I think,

1:15:55

is that so many people

1:15:56

know people

1:15:57

that have had

1:15:58

stem cell treatment

1:15:58

and have had

1:16:00

amazing results,

1:16:01

like with injuries

1:16:02

that they just couldn't

1:16:03

recover from.

1:16:04

Yeah.

1:16:04

And unfortunately,

1:16:06

some of them

1:16:06

had to go to Panama

1:16:07

and had to go to Tijuana

1:16:09

and Colombia

1:16:09

and all these different places

1:16:10

where it's legal.

1:16:11

Yep.

1:16:11

And that's,

1:16:13

I can't tell you

1:16:15

how many people

1:16:15

that I've talked to

1:16:16

that have an injury

1:16:17

and say,

1:16:18

hey, I'm thinking

1:16:18

about going to Tijuana.

1:16:20

What do you think?

1:16:21

And I say,

1:16:21

it'll help you.

1:16:22

100%.

1:16:23

I've talked to my dad,

1:16:24

he went,

1:16:25

I talked to my uncle,

1:16:26

my grandma went,

1:16:27

this person went,

1:16:28

that person went.

1:16:28

They had results

1:16:29

that they never achieved

1:16:31

doing any other things.

1:16:32

Why is this not available here?

1:16:34

I'm like,

1:16:34

oh man,

1:16:34

it's a long story.

1:16:35

I can't even

1:16:36

start this conversation.

1:16:38

I have to go.

1:16:39

Well,

1:16:40

and what's amazing though

1:16:41

is I'm telling you

1:16:43

we're,

1:16:43

we,

1:16:43

having got to know

1:16:46

Senator Colhurst

1:16:47

and Lacey Hull,

1:16:48

the representative here,

1:16:49

we'll get it done

1:16:51

in Texas.

1:16:51

Like it's coming.

1:16:52

It's the new bill

1:16:53

that we're going to

1:16:54

submit in January.

1:16:55

I feel confident

1:16:56

that we will

1:16:58

expand upon

1:16:59

on the existing

1:17:00

legislation

1:17:01

around patient

1:17:03

right to choose

1:17:04

because I think

1:17:05

it's important

1:17:05

to begin to hedge

1:17:06

against the power

1:17:07

of big pharma

1:17:08

and to try to build

1:17:09

out a model

1:17:09

with peptides

1:17:10

and other things

1:17:11

that we include

1:17:12

in this bill

1:17:12

at the state level

1:17:13

just in case,

1:17:15

you know,

1:17:15

just in case,

1:17:16

not even this administration.

1:17:18

I feel very confident

1:17:19

this administration

1:17:20

is going to get

1:17:20

a lot of these things done

1:17:21

but then what happens

1:17:23

as soon as

1:17:24

there's a change

1:17:25

in power down the road

1:17:26

and how many years

1:17:27

can you fight this lobby,

1:17:28

right?

1:17:29

It's still alive

1:17:30

and well.

1:17:30

It's not going anywhere

1:17:31

but I think it's crucial

1:17:33

that we fight

1:17:34

for sovereignty

1:17:34

and autonomy

1:17:35

over our health

1:17:36

and continue to push.

1:17:39

I can tell you

1:17:40

at the state level

1:17:41

I'm very,

1:17:43

very bullish

1:17:43

that it will happen

1:17:45

and what Florida saw

1:17:46

is a $300 million

1:17:47

infusion of cash

1:17:50

into the state of Florida

1:17:51

built all around this

1:17:52

because it's now

1:17:53

a medical tourism destination

1:17:55

and that's my message

1:17:57

to these senators

1:17:57

and congressmen

1:17:59

and congresswomen

1:17:59

in Texas

1:17:59

is we have

1:18:01

a legitimate opportunity

1:18:02

to do what you did

1:18:04

with the food bill

1:18:05

and the Maha movement

1:18:06

around these initiatives

1:18:07

to drive home

1:18:09

these same initiatives

1:18:10

on longevity

1:18:11

and preventative base care

1:18:13

in the state of Texas.

1:18:14

We have an opportunity

1:18:15

to turn Texas

1:18:16

into a medical tourism destination.

1:18:18

Can you imagine

1:18:20

how many people

1:18:21

would visit Austin

1:18:22

if we truly do build

1:18:24

a proper regulatory pathway

1:18:26

with all the checks

1:18:27

and balances

1:18:28

where people can confidently

1:18:29

fly down here

1:18:30

and know that they can

1:18:31

get these treatments?

1:18:32

And not have to have

1:18:32

a passport.

1:18:33

Yeah.

1:18:33

I mean,

1:18:34

because this is what's going on.

1:18:35

This is why people

1:18:36

are going to Panama

1:18:36

and all these other places.

1:18:38

Yeah.

1:18:39

I mean,

1:18:39

they're desperate

1:18:40

and so they're willing

1:18:41

to leave the country.

1:18:42

Yeah.

1:18:42

100%.

1:18:44

It would be way easier

1:18:46

to just hop on a Southwest flight,

1:18:47

come to Austin,

1:18:48

pretty easy,

1:18:49

a lot easier,

1:18:51

and it should be available.

1:18:52

And what's really amazing to me

1:18:54

with the Maha movement

1:18:56

is watching people scramble

1:18:58

to find some sort of narrative

1:19:01

as to what they're doing

1:19:03

is dangerous

1:19:03

or what they're doing is bad

1:19:05

or what they're doing

1:19:06

is somehow or another

1:19:08

not the way we should be going,

1:19:10

ignoring those facts

1:19:12

that you laid out.

1:19:13

We are the wealthiest country

1:19:14

in the world.

1:19:14

We are the sickest country

1:19:16

in the world.

1:19:16

We've never had more money.

1:19:18

We've never been more sick.

1:19:19

Yeah.

1:19:20

We've never spent more

1:19:21

on healthcare.

1:19:21

We've never been more fucked up.

1:19:23

Yeah.

1:19:23

At one point in time,

1:19:25

does someone say,

1:19:26

hey, this system sucks.

1:19:28

Yeah.

1:19:28

But they don't want to.

1:19:30

They don't want,

1:19:31

they resist this radical change

1:19:33

and this appeal to authority

1:19:34

that these people

1:19:35

that are in control

1:19:36

of all these various organizations,

1:19:39

they know what they're doing.

1:19:40

They are the experts.

1:19:42

We should trust them.

1:19:43

They've fucked this whole thing up.

1:19:45

How are you trusting them still?

1:19:47

When you just said

1:19:48

60 to 80% of them

1:19:50

have either major label changes

1:19:51

or have the products removed,

1:19:53

you think about

1:19:54

all the different

1:19:55

adverse side effects

1:19:56

that are very,

1:19:56

very well known

1:19:58

from various pharmaceutical drugs,

1:19:59

all these different things.

1:20:01

How many times

1:20:03

does this have to happen

1:20:04

before you just want

1:20:05

to rip that Band-Aid off

1:20:06

and do something different?

1:20:08

It's tough because,

1:20:10

and people misunderstand.

1:20:11

I think they misunderstand

1:20:12

even what you and I are saying

1:20:13

because I hear so often

1:20:14

people going,

1:20:15

okay,

1:20:15

it's a conspiracy theory.

1:20:17

They want to keep you fat

1:20:18

and sick

1:20:19

and monetize chronic disease

1:20:20

and there's malicious intent.

1:20:22

I'm like,

1:20:22

no.

1:20:22

What I'm telling you

1:20:24

is this system

1:20:25

was born in captivity.

1:20:26

It's broken.

1:20:27

There's special interests

1:20:28

that are able

1:20:29

to influence accessibility

1:20:31

and affordability of care.

1:20:33

Those decisions

1:20:34

have cataclysmic effects

1:20:38

on our health

1:20:39

as a nation

1:20:39

and on our national security,

1:20:41

how many men

1:20:42

can even qualify

1:20:43

for military service right now?

1:20:45

71% of young kids

1:20:47

can't qualify

1:20:48

for military service.

1:20:49

It's nuts.

1:20:49

And then you look at

1:20:50

how many can't even do,

1:20:52

I think,

1:20:52

I don't remember

1:20:52

what the number,

1:20:53

it was something staggering,

1:20:54

like the average American

1:20:55

can't do two pull-ups

1:20:56

or something like that.

1:20:57

And then you see

1:20:58

Secretary Kennedy

1:20:58

rattling off

1:20:59

20-something pull-ups

1:21:00

at the airport.

1:21:01

At 70.

1:21:01

Which is nuts.

1:21:03

But it's not that,

1:21:06

I'm not saying anyone...

1:21:07

It's not a conspiracy.

1:21:08

It's just,

1:21:09

they are extracting

1:21:11

enormous amounts of money.

1:21:12

They don't want to stop

1:21:14

extracting enormous amounts of money.

1:21:17

They want the system

1:21:18

to remain in place as is

1:21:21

because it's very profitable for them.

1:21:23

But it's just not good for us.

1:21:25

Correct.

1:21:25

And it doesn't mean

1:21:26

it can't be profitable still.

1:21:28

Yeah.

1:21:28

It's just,

1:21:29

you have to have

1:21:30

a workable,

1:21:31

functional model

1:21:32

that benefits

1:21:32

the American people

1:21:34

and benefits health.

1:21:35

I agree.

1:21:36

And that's where I'm like,

1:21:37

guys,

1:21:37

we don't have to...

1:21:38

I'm not saying

1:21:39

if you want to run this system

1:21:41

the way you're running it

1:21:41

and reform it where you can,

1:21:43

I get that.

1:21:44

But I also think

1:21:45

there's an immense value

1:21:46

in building a life raft

1:21:47

just in case.

1:21:48

Just in case.

1:21:49

Why is there any pushback

1:21:52

to building a cash pay model

1:21:54

with a pathway

1:21:56

that allows patients

1:21:57

to access medications

1:21:58

with their own hard-earned cash?

1:22:01

preventative health care

1:22:02

instead of sick care.

1:22:03

You got it.

1:22:04

Sick care that is perpetual

1:22:05

and never-ending

1:22:06

and ultimately leads

1:22:08

to a catastrophic

1:22:09

series of side effects.

1:22:10

You got it.

1:22:11

Yeah.

1:22:12

And I tell people

1:22:13

the difference is

1:22:14

with a peptide

1:22:15

or something preventative,

1:22:16

you're coming in

1:22:17

and we're optimizing you.

1:22:19

Right?

1:22:20

So, you know,

1:22:20

I've taken things

1:22:21

like Dihexa.

1:22:22

You know,

1:22:23

for me personally,

1:22:24

I'm not advertising

1:22:24

this for other people

1:22:26

but it's like

1:22:27

it 100% improved

1:22:29

my neurocognitive function.

1:22:30

It 100% improved

1:22:31

my data recall

1:22:32

and retention.

1:22:33

It moved the needle

1:22:34

and I'm paying

1:22:36

with my cash

1:22:36

to use something

1:22:38

that is doctor-prescribed

1:22:39

and why do I need

1:22:42

anyone else's approval

1:22:43

for that?

1:22:43

I understand the need

1:22:44

to protect the American public

1:22:46

with safety

1:22:47

and that's where I think

1:22:48

improving safety

1:22:49

is important

1:22:50

but the second part

1:22:51

of the equation

1:22:52

with the FDA

1:22:52

is approving efficacy

1:22:54

and approving efficacy

1:22:55

unfortunately with the model

1:22:57

is a multi-billion dollar process.

1:22:59

Those checks and balances

1:23:01

are crucial

1:23:02

when you do a set it

1:23:04

and forget it

1:23:04

healthcare system.

1:23:05

What do I mean by that?

1:23:06

You put somebody on Lipitor

1:23:08

and the doctor doesn't see them

1:23:09

for another year

1:23:10

and that patient

1:23:11

is blindly trusting

1:23:13

that clinician.

1:23:13

That is the insurance model.

1:23:15

The cash pay model

1:23:17

is an educated pay

1:23:19

patient

1:23:19

who's taking their health

1:23:21

into their own hands

1:23:23

and you better believe me

1:23:24

when I say

1:23:25

if you don't put a win

1:23:26

on the board

1:23:27

they're going to fire your ass

1:23:29

because it's their money.

1:23:30

Nobody's going to take

1:23:31

a peptide month

1:23:32

after month

1:23:33

after month

1:23:33

if they don't think

1:23:34

it's doing anything

1:23:35

because they're using their money

1:23:37

not taxpayers money

1:23:39

not an employer's money

1:23:40

right?

1:23:41

The checks and balances

1:23:42

are there

1:23:43

through the consumer market

1:23:44

because it has more integrity

1:23:47

than the traditional model

1:23:49

because this is the only model

1:23:50

where if you don't produce

1:23:52

for the patient

1:23:52

you're fired.

1:23:53

You can't fire your clinician

1:23:56

in the insurance model

1:23:57

because the insurance model

1:23:58

tells you where to go.

1:24:00

And this is an important point

1:24:01

sorry I'm ADHD

1:24:02

but I'm thinking about this

1:24:03

one of the things

1:24:03

that a regulator mentioned to me

1:24:05

was

1:24:05

again

1:24:06

I hate to keep bringing up

1:24:07

these big pharmaceutical companies

1:24:08

but they were lobbying

1:24:09

saying

1:24:10

there's a problem

1:24:11

guys like Brigham

1:24:12

they'll own the pharmacy

1:24:14

but then they also own clinics

1:24:16

and that's vertical integration

1:24:17

and blah blah blah blah blah

1:24:19

and that's not fair to a patient.

1:24:20

Hold on

1:24:21

if you understand

1:24:22

the law of the land

1:24:23

the patient has the right

1:24:25

to take their prescription

1:24:26

wherever they want

1:24:27

even if they come

1:24:29

two ways too well

1:24:30

we may prescribe it

1:24:31

and we send it to me

1:24:33

to my pharmacy

1:24:34

because we compete on price

1:24:36

and I'm going to make this

1:24:37

as cost effective

1:24:38

and as beneficial

1:24:39

to the patient as possible

1:24:40

if I can't compete

1:24:42

in an open market

1:24:43

and make this affordable

1:24:44

and approachable for you

1:24:45

take your prescription

1:24:47

somewhere else

1:24:48

but I'm going to provide

1:24:49

quality, efficacy

1:24:50

and cost

1:24:51

and I'm going to beat you

1:24:53

you're not going to force people

1:24:54

to only get that medication

1:24:55

and what people don't understand

1:24:56

is in the insurance model

1:24:57

a patient is told

1:24:59

you're not allowed

1:25:00

to go to this doctor

1:25:01

you got to go to this doctor

1:25:02

because they're within your plan

1:25:03

and then they go to that doctor

1:25:05

and that doctor goes

1:25:06

what pharmacy do you want

1:25:07

to fill that

1:25:07

well it doesn't matter

1:25:09

if it's CVS

1:25:09

or Walgreens or wherever

1:25:11

the patient's going to have

1:25:12

the same price

1:25:13

because that price

1:25:14

is controlled by the PBM

1:25:15

which is the insurance company

1:25:17

and then that PBM

1:25:18

is monetizing that drug

1:25:19

through rebate programs

1:25:20

it is a totally different

1:25:22

system

1:25:23

that captures a patient

1:25:25

controls a patient

1:25:26

and monetizes chronic disease

1:25:28

my goal

1:25:29

is to help you

1:25:31

drive healthspan

1:25:32

and monetize your health

1:25:33

to help you

1:25:35

want to be a willing participant

1:25:36

because you feel so good

1:25:38

and your mental

1:25:39

cognitive

1:25:40

physical function

1:25:41

your skin

1:25:41

your complexion

1:25:42

what we see

1:25:44

is somebody starts

1:25:45

and it's not

1:25:47

they start thinking

1:25:48

they want to lose weight

1:25:49

guess what

1:25:50

but as soon as a guy

1:25:51

like Jelly loses that weight

1:25:52

now the guy

1:25:52

I was on the phone

1:25:53

with him this morning

1:25:54

he's running five miles

1:25:55

talking to me on the phone

1:25:56

this was a guy

1:25:57

who was 500 pounds

1:25:59

man

1:25:59

this is a guy who couldn't

1:25:59

walk up his driveway

1:26:00

and now he has life again

1:26:02

he's bow hunting

1:26:03

he's like getting into

1:26:04

these hobbies

1:26:04

and these things

1:26:05

when he goes and spends

1:26:07

money on a peptide

1:26:08

it's not because

1:26:09

it's pseudoscience

1:26:10

or it doesn't work

1:26:11

it's because he's a living

1:26:12

example of the impact

1:26:13

it's made on his life

1:26:14

and he is knowingly

1:26:16

and willingly

1:26:17

opting in

1:26:18

to continue to see

1:26:20

how far he can push

1:26:21

this healthcare journey

1:26:22

and how much more

1:26:23

optimal he can get

1:26:24

and in real time

1:26:26

unlike traditional medicine

1:26:28

we are tracking

1:26:29

all of this shit

1:26:30

we're tracking you

1:26:32

via DEXA

1:26:32

we're tracking you

1:26:33

via VO2 max

1:26:34

we're tracking you

1:26:35

via wearables

1:26:36

all of that vertically

1:26:38

integrated in real time

1:26:39

and then we're culminating

1:26:40

that data

1:26:41

across the patient population

1:26:43

so imagine when I get

1:26:44

to a point

1:26:45

in a dream world

1:26:47

what I want is

1:26:48

10-15 million patients

1:26:50

nationwide

1:26:50

we're tracking

1:26:51

all these data analytics

1:26:53

we know that every man

1:26:54

with a gene marker

1:26:56

of P452

1:26:57

who went on testosterone

1:26:59

saw a marked improvement

1:27:00

in REM sleep

1:27:01

right

1:27:02

this is all the type of data

1:27:03

we can extrapolate

1:27:04

but to do that

1:27:06

you've got to have the tools

1:27:07

you've got to have

1:27:08

the peptides

1:27:09

you've got to have

1:27:10

the biologics

1:27:11

you've got to have

1:27:12

the diagnostic tools

1:27:14

like comprehensive blood work

1:27:15

another huge missed thing

1:27:17

in healthcare

1:27:18

and I believe

1:27:19

is gene sequencing

1:27:20

less than 1 in 1,000 people

1:27:22

have ever had

1:27:23

their genome sequenced

1:27:24

we've only sequenced

1:27:26

I think 1 in 1,000 animals

1:27:28

genetics is on the

1:27:30

is in the infancy

1:27:33

of what it's going to be

1:27:34

and a real world example

1:27:36

of that is somebody

1:27:37

like Gordon

1:27:37

who we've been trying to help

1:27:38

and sorry

1:27:40

I know I'm dumping a lie

1:27:41

I want to be clear

1:27:42

I'm not a doctor

1:27:43

right

1:27:44

I'm just a guy

1:27:45

who's trying to solve problems

1:27:46

and everything

1:27:47

that I talk about today

1:27:49

is not me being

1:27:50

a bro science

1:27:52

or me

1:27:52

trying to be an influencer

1:27:54

or the things

1:27:55

that people try to say

1:27:56

everything I discuss

1:27:57

comes from my mentors

1:27:59

and my mentor

1:28:01

is my chief science officer

1:28:02

Ian White

1:28:03

22 years

1:28:03

stem cell research

1:28:04

Harvard and Sare

1:28:05

Stem Cell Institute

1:28:06

Mari Dazawa

1:28:09

who discovered

1:28:11

mu cells

1:28:12

from Japan

1:28:13

and is one of the pioneers

1:28:15

in stem cell research

1:28:16

Mari is an absolute badass

1:28:18

Dr. Deutcher

1:28:20

Stanford graduate

1:28:22

stem cell research

1:28:24

longevity specialist

1:28:25

Ryan Rossner

1:28:26

PhD

1:28:26

worked for DARPA

1:28:28

I'm talking to brilliant people

1:28:30

and I'm doing my best

1:28:31

to learn and distill down

1:28:33

what I'm gathering

1:28:34

from these folks

1:28:35

in a manner that's digestible

1:28:36

for Neanderthals like myself

1:28:38

that's all I'm trying to do

1:28:40

you guys at Ways to Well

1:28:41

are also incorporating

1:28:42

a bunch of other therapies

1:28:44

and I want you to talk

1:28:45

about those too

1:28:46

yeah

1:28:47

I would love to

1:28:48

before I lose

1:28:49

real quick on the genetics

1:28:50

because I'm super excited

1:28:52

about this

1:28:52

so one of the things

1:28:53

we're building into the app

1:28:54

so the next generation

1:28:55

of the app

1:28:56

which will come out

1:28:56

in a few weeks

1:28:57

we're just trying

1:28:58

to improve on

1:28:59

the simplicity of use

1:29:01

the ability to get refills

1:29:03

vertically integrating

1:29:03

into a pharmacy

1:29:04

because so often

1:29:06

patients will fill

1:29:07

a prescription

1:29:07

go to a pharmacy

1:29:09

they don't know

1:29:09

then they come back

1:29:10

and they go

1:29:11

where am I in the refill

1:29:12

and where is it at

1:29:13

in the process

1:29:13

and when does it get

1:29:14

to my house

1:29:15

and what about this

1:29:15

and what about that

1:29:16

and I can't remember

1:29:17

what the doctor said

1:29:18

on the phone

1:29:18

that was the whole point

1:29:19

of Alan

1:29:20

the chat bot

1:29:21

that I showed you

1:29:21

years ago

1:29:22

Alan is a resource

1:29:23

in your pocket

1:29:24

and Alan is there

1:29:25

to pull from your

1:29:26

medical records

1:29:27

to pull from your chart

1:29:28

in real time

1:29:30

to answer any question

1:29:31

about what happened

1:29:32

on that phone consult

1:29:33

with that clinician

1:29:33

because all of that's

1:29:35

annotated

1:29:35

and put into the system

1:29:37

and documented

1:29:38

and so Alan is there

1:29:39

to help answer

1:29:40

and fill in the gaps

1:29:41

and where I was going

1:29:42

with this earlier

1:29:43

is through large language

1:29:44

models in AI

1:29:45

we're going to be able

1:29:46

to scale

1:29:47

concierge medicine

1:29:48

we're going to be able

1:29:49

to scale it in a way

1:29:50

like never before

1:29:51

that allows patients

1:29:53

to get that high touch

1:29:55

high quality care

1:29:56

but for pennies

1:29:58

on the dollar

1:29:58

like my goal

1:29:59

is to make this

1:30:00

as cheap as possible

1:30:01

so everybody

1:30:02

can afford it

1:30:03

and that's the goal

1:30:04

with stem cells too

1:30:05

but it starts

1:30:06

with regulatory pathways

1:30:07

and de-stigmatizing

1:30:10

these treatments

1:30:10

and building a pathway

1:30:12

that everyone can afford

1:30:13

and so one of the things

1:30:15

we're looking to add

1:30:16

to the app

1:30:16

is gene sequencing

1:30:18

there are 20,000 genes

1:30:20

most people don't have

1:30:22

any clue

1:30:23

what genes they have

1:30:24

and the reason

1:30:25

that's important

1:30:26

and what my buddy

1:30:27

Ryan Rossner will tell you

1:30:28

is he's a geneticist

1:30:29

is your genes

1:30:32

are the software

1:30:33

that are telling

1:30:34

the computer how to run

1:30:35

is this the guy

1:30:35

that I met

1:30:36

yeah

1:30:36

yeah yeah

1:30:37

and he worked brilliant

1:30:39

worked for DARPA

1:30:40

tons of experience

1:30:42

at the bench

1:30:43

in the lab

1:30:44

doing genetic research

1:30:46

the stuff he did

1:30:48

for DARPA

1:30:48

was crazy

1:30:49

I mean when he starts

1:30:50

telling you

1:30:50

you know

1:30:51

one of the things

1:30:51

he said is

1:30:52

we're in an era

1:30:53

where we can build

1:30:54

real life X-Men

1:30:55

like we can build

1:30:57

X-Men

1:30:57

there's a gene

1:30:58

a gene editing injection

1:31:01

that can make

1:31:01

your bone mineral density

1:31:02

eight times stronger

1:31:03

what?

1:31:04

yeah

1:31:04

I mean there's

1:31:05

like you could do that?

1:31:07

it's that

1:31:08

you can't legally do it

1:31:09

in the US right now

1:31:10

these are things

1:31:11

that they're doing

1:31:11

are they making

1:31:12

Russian super soldiers

1:31:13

right now?

1:31:13

this is the challenge

1:31:14

it's China and Russia

1:31:15

are pushing the envelope

1:31:17

with all these things

1:31:18

does that change

1:31:18

your body mass?

1:31:19

it'd be interesting

1:31:20

I didn't dig in

1:31:21

with him on that

1:31:22

but it would have to

1:31:23

right?

1:31:23

you would 100%

1:31:25

think it's going to

1:31:25

change your BMI

1:31:26

because your bone mineral

1:31:27

is going to be

1:31:27

much thicker

1:31:28

and more dense

1:31:29

you'd probably be

1:31:29

a lot heavier

1:31:30

so it's going to

1:31:31

change your

1:31:32

DEXA scan

1:31:33

and your readings

1:31:34

yeah

1:31:34

whoa

1:31:35

but the future

1:31:36

to me

1:31:36

I want that

1:31:37

I'm telling you

1:31:38

the future

1:31:38

I want to run through

1:31:39

walls

1:31:40

on that

1:31:40

it's a reddit post

1:31:42

that says

1:31:42

there's a mutation

1:31:42

that causes bones

1:31:43

to become eight times

1:31:44

denser than normal

1:31:45

but the tradeoff

1:31:46

is not being able

1:31:47

to swim

1:31:47

well I can barely

1:31:49

swim right now

1:31:50

as it is man

1:31:51

I sink like a

1:31:52

fucking stone

1:31:53

as it is

1:31:53

it's a real problem

1:31:54

where one of the

1:31:56

things that he's

1:31:57

enlightened me on

1:31:57

because I'm not

1:31:58

a geneticist

1:31:59

I don't know

1:31:59

anything about

1:32:00

that world

1:32:00

he's like

1:32:01

dude if you do

1:32:02

a gene sequencing

1:32:03

test on a guy

1:32:04

like Gordon Ryan

1:32:05

maybe there's a gene

1:32:06

that's causing him

1:32:07

to have these

1:32:08

stomach issues

1:32:08

so we run

1:32:09

the full gene

1:32:10

sequencing on Gordon

1:32:11

at ways to well

1:32:13

and it comes back

1:32:14

and you know

1:32:15

offhand I remember

1:32:16

there's a couple

1:32:16

of really interesting

1:32:17

stuff

1:32:18

Gordon has a gene

1:32:20

that is like

1:32:21

one in ten million

1:32:22

that makes your

1:32:24

tendons

1:32:24

more dense

1:32:26

and more resilient

1:32:27

so stronger

1:32:28

more rigid

1:32:30

tendons

1:32:31

that are able to

1:32:32

are more resilient

1:32:33

to damage

1:32:34

boy does that

1:32:35

make sense

1:32:35

yeah

1:32:36

he has that gene

1:32:37

he also has a gene

1:32:38

that makes his

1:32:39

propensity to have

1:32:40

bone mineral density

1:32:41

higher

1:32:41

that's why his

1:32:42

bone mineral density

1:32:43

is higher

1:32:43

that's why his

1:32:44

bones don't break

1:32:44

as easy

1:32:45

those are some

1:32:46

of the positives

1:32:47

that are in his

1:32:48

firmware

1:32:48

his software

1:32:49

that's running

1:32:49

the biology

1:32:50

that is Gordon

1:32:51

Ryan

1:32:51

now some of the

1:32:52

downside

1:32:53

and this is

1:32:53

this is a really

1:32:54

cool one

1:32:54

because we've been

1:32:55

trying to help

1:32:56

Gordon with this

1:32:56

gut health issue

1:32:57

for years

1:32:58

and it's this

1:32:58

constant battle

1:32:59

of you know

1:33:00

he's getting

1:33:00

staph

1:33:01

now he's on

1:33:01

antibiotics

1:33:02

now his gut

1:33:03

health's wrecked

1:33:03

again

1:33:03

a lot of that

1:33:05

comes down to

1:33:05

he has a gene

1:33:06

marker that puts

1:33:07

him at a

1:33:07

predisposition

1:33:08

to get staph

1:33:09

he has a weakened

1:33:11

immune system

1:33:12

so now he's in

1:33:13

an environment

1:33:14

where he's being

1:33:14

exposed to a

1:33:15

chronic issue

1:33:17

and he has a

1:33:18

predisposition

1:33:18

to not be

1:33:20

resilient to that

1:33:21

issue

1:33:21

and then he also

1:33:23

has a gene

1:33:23

marker

1:33:24

that makes his

1:33:25

gut health

1:33:26

more acidic

1:33:28

and so these are

1:33:29

like rare genes

1:33:30

and he happens

1:33:31

to have these

1:33:31

anomalies

1:33:32

so it's like

1:33:33

in one hand

1:33:33

he has this

1:33:34

perfect

1:33:34

won the

1:33:36

statistical lottery

1:33:37

genetic traits

1:33:38

that put him

1:33:39

in a position

1:33:39

to potentially

1:33:40

be an amazing

1:33:41

grappler

1:33:42

and athlete

1:33:43

but then he

1:33:44

has this

1:33:44

Achilles heel

1:33:45

of his

1:33:46

predisposition

1:33:47

to infections

1:33:48

and his

1:33:49

body's gut

1:33:49

health

1:33:50

and gut

1:33:50

biome

1:33:51

issues

1:33:51

are all

1:33:52

in that gene

1:33:53

they're all

1:33:53

in the software

1:33:54

and so the

1:33:55

premise that

1:33:55

Ryan

1:33:56

and what we're

1:33:56

trying to

1:33:56

evolve and build

1:33:57

out

1:33:58

20,000 genes

1:34:01

most people

1:34:02

don't have any

1:34:03

clue what any

1:34:04

of their genes

1:34:04

are

1:34:04

we're taking

1:34:07

all of the

1:34:07

knowledge that

1:34:08

Ryan and these

1:34:09

geneticists have

1:34:09

and we're trying

1:34:10

to automate it

1:34:11

using the large

1:34:11

language models

1:34:12

and AI

1:34:12

and build that

1:34:14

into the

1:34:14

Ways to Well

1:34:15

app

1:34:15

so alongside

1:34:16

with you know

1:34:17

the VO2 max

1:34:18

the DEXA

1:34:18

go get those

1:34:19

anywhere

1:34:20

I'm not trying

1:34:21

to sell you

1:34:22

these things

1:34:22

I just want

1:34:23

the information

1:34:24

so I can

1:34:24

help you

1:34:25

I don't give

1:34:26

a shit

1:34:27

go get your

1:34:27

blood work

1:34:28

from whoever

1:34:29

if you can

1:34:29

get insurance

1:34:30

to cover it

1:34:31

do it

1:34:31

if you can

1:34:32

get insurance

1:34:32

to help you

1:34:33

with a VO2 max

1:34:34

or a DEXA

1:34:34

do it

1:34:35

they're not

1:34:35

they're not

1:34:36

going to

1:34:36

but shop it

1:34:37

find the best

1:34:38

place for you

1:34:38

and then if you

1:34:39

have that data

1:34:40

when we launch

1:34:41

the new app

1:34:42

we can load

1:34:43

all that into

1:34:43

the large language

1:34:44

models

1:34:44

we can load

1:34:45

in your gene

1:34:46

sequencing

1:34:46

we can begin

1:34:47

to look at you

1:34:48

at a much

1:34:49

broader level

1:34:50

to try and figure

1:34:52

out

1:34:52

where are you

1:34:54

headed

1:34:54

and why

1:34:55

what gene

1:34:56

dispositions

1:34:57

do you have

1:34:58

and how do we

1:34:59

help you

1:34:59

navigate that

1:35:00

that's predictive

1:35:02

medicine

1:35:03

that's personalized

1:35:04

medicine

1:35:05

and nobody's

1:35:07

doing anything

1:35:07

with genes

1:35:08

right now

1:35:08

it's great

1:35:10

everyone

1:35:10

we just got

1:35:11

people sold

1:35:12

on being able

1:35:12

to do blood work

1:35:13

and people are

1:35:14

acting like

1:35:14

that's the holy

1:35:15

grail

1:35:15

and like

1:35:16

I'm a believer

1:35:17

in blood work

1:35:17

but it's a snapshot

1:35:18

of you in time

1:35:19

right

1:35:20

that's a moment

1:35:20

of you in time

1:35:21

what did you eat

1:35:22

that day

1:35:22

how did you sleep

1:35:23

the day before

1:35:24

when did you take

1:35:24

your testosterone

1:35:25

like there's a million

1:35:27

variables that can

1:35:27

throw off your blood

1:35:28

work

1:35:28

you can't lie

1:35:30

on a dexa

1:35:30

I mean that's a real

1:35:32

analysis of your

1:35:33

visceral fat

1:35:34

your subcutaneous fat

1:35:35

how much fat's packed

1:35:36

in around your organs

1:35:38

we're gonna know

1:35:38

all that

1:35:39

how much atrophies

1:35:40

on your left bicep

1:35:41

versus your right bicep

1:35:42

all of those things

1:35:44

like Liam Harrison

1:35:45

was just in

1:35:45

I know you and Liam

1:35:47

are buddies

1:35:48

he was shocked

1:35:50

because he has

1:35:51

that one

1:35:51

bum knee

1:35:52

from all those

1:35:53

years of Muay Thai

1:35:54

and the fighters

1:35:55

just started

1:35:55

picking off his knee

1:35:56

what's crazy

1:35:57

is he thought

1:35:58

he would have

1:35:58

less muscle

1:35:59

on that knee

1:35:59

than that leg

1:36:00

than the other leg

1:36:01

because he's

1:36:02

overcompensated

1:36:03

and trained it

1:36:03

so much

1:36:04

he had more

1:36:04

muscle mass

1:36:05

on the bum leg

1:36:06

than on the

1:36:07

what he thought

1:36:08

was his strong leg

1:36:09

and so he was

1:36:10

like shocked

1:36:10

by that

1:36:11

but it's fascinating

1:36:12

because it's just

1:36:13

data right

1:36:14

and that data

1:36:15

gives you the ability

1:36:16

to navigate

1:36:16

and it gives us

1:36:17

a blueprint

1:36:18

because now

1:36:19

with that data

1:36:20

I know things

1:36:21

like we know

1:36:23

how much bone

1:36:23

mineral density

1:36:24

you're gonna lose

1:36:24

year after year

1:36:25

once you reach

1:36:26

a certain age

1:36:27

we can begin

1:36:28

to quantify that

1:36:29

and model out

1:36:31

your vertebral

1:36:31

risk fracture risk

1:36:33

you know

1:36:34

your hip fracture risk

1:36:35

how do we preserve

1:36:36

bone mineral density

1:36:37

like it allows us

1:36:39

to quantify

1:36:39

are the hormones

1:36:40

and these things

1:36:41

helping preserve

1:36:42

lean muscle mass

1:36:43

keep the body fat off

1:36:44

and optimize bone health

1:36:46

all of these things

1:36:47

and with

1:36:48

with what this FDA

1:36:49

is doing

1:36:50

with men's health

1:36:51

and women's health

1:36:52

and fertility

1:36:52

and the direction

1:36:53

it's headed

1:36:54

I really think

1:36:55

we have the potential

1:36:57

if we pull this off

1:36:58

to enter

1:36:59

a golden era

1:37:00

of health care

1:37:01

I really believe that

1:37:02

but it is gonna require

1:37:03

thinking on orthodox

1:37:05

it is gonna require

1:37:06

a cash pay model

1:37:07

I don't think

1:37:08

we can overhaul

1:37:09

a system

1:37:10

and build in

1:37:11

all these different

1:37:12

modalities

1:37:12

I don't think

1:37:14

we could get it done

1:37:15

in a decade

1:37:15

you know

1:37:16

I really don't

1:37:17

and then how many lives

1:37:18

are lost in that time

1:37:19

that's where I'm pleading

1:37:20

for

1:37:21

let's build a cash pay model

1:37:23

that is a life raft

1:37:24

that's an alternative

1:37:24

and let's build a pathway

1:37:26

that makes sense

1:37:27

that maybe is a more

1:37:29

nuanced approach

1:37:30

to driving health span

1:37:31

because I know

1:37:32

for a fact

1:37:33

Secretary Kennedy

1:37:34

has said

1:37:34

his goal

1:37:35

is to leave a legacy

1:37:37

that transitioned

1:37:38

our broken sick care system

1:37:40

into a health care system

1:37:42

into one that prevents

1:37:44

chronic disease

1:37:44

rather than monetizing

1:37:46

chronic disease

1:37:47

that has literally

1:37:48

been the mission statement

1:37:49

since the day

1:37:50

we opened our fucking doors

1:37:51

I'm like

1:37:52

that's all we're trying to do

1:37:53

and I love it

1:37:55

because then you get

1:37:55

into the fun shit

1:37:56

like

1:37:56

where do we go

1:37:58

with all this

1:37:58

gene activation

1:38:00

and where do we go

1:38:01

with like

1:38:01

the ability

1:38:02

to optimize humans

1:38:03

right

1:38:04

rather than just

1:38:05

trying to keep you

1:38:06

from being sick

1:38:07

we should strive

1:38:09

to make you superhuman

1:38:11

I mean that's really

1:38:12

my belief

1:38:12

like

1:38:12

why do you want

1:38:13

to have normal hormones

1:38:14

when you can have

1:38:15

optimal hormones

1:38:16

normal bone mineral density

1:38:18

when you can have

1:38:19

optimal bone mineral density

1:38:20

that's what I'm talking about

1:38:21

on all of these things

1:38:22

so let me ask you this

1:38:23

about the gene stuff

1:38:23

what do they do

1:38:26

so if they find out

1:38:27

that you have an issue

1:38:28

you have some sort

1:38:29

of a genetic issue

1:38:30

that prevents you

1:38:31

from doing x y or z

1:38:33

what can they do

1:38:34

with your genes

1:38:35

so it varies by gene

1:38:37

but it gives us

1:38:38

it gives us the reason

1:38:39

to try and understand

1:38:40

oh okay

1:38:42

this is why

1:38:43

this has been

1:38:45

a repetitive issue

1:38:45

and it begins to give you

1:38:47

answers to the test

1:38:49

so you're not taking

1:38:50

a shot in the dark

1:38:51

and those answers

1:38:52

will allow us to

1:38:53

hopefully tailor

1:38:54

and develop nuanced treatments

1:38:56

now the future

1:38:57

is they're able

1:38:59

to turn off

1:38:59

and on genes

1:39:00

like a light switch

1:39:01

I don't know

1:39:02

if you saw

1:39:02

like they just

1:39:03

there was a whole article

1:39:04

about they discovered

1:39:05

that whales

1:39:06

have a protein

1:39:07

unique to whales

1:39:08

and they live

1:39:08

over 200 years

1:39:10

and they think

1:39:10

this protein

1:39:11

could be

1:39:12

one of the keys

1:39:13

to driving human health

1:39:14

span and longevity

1:39:15

and it's basically

1:39:16

the premise is

1:39:17

can we synthesize

1:39:18

and utilize

1:39:19

this gene

1:39:21

to turn on

1:39:22

the gene

1:39:22

in humans

1:39:23

and have us

1:39:24

secrete

1:39:24

and produce

1:39:25

a higher level

1:39:25

of this protein

1:39:26

or this amino acid

1:39:27

and would it drive

1:39:28

our health span

1:39:29

and reduce our risk

1:39:30

of cancers

1:39:30

all of those things

1:39:32

so the question becomes

1:39:34

as we evolve

1:39:35

what genes

1:39:37

can we turn on

1:39:37

and turn off

1:39:38

you know

1:39:39

what does the regulatory

1:39:40

landscape of the future

1:39:41

look like in America

1:39:42

China and Russia

1:39:43

are already doing

1:39:44

these things

1:39:44

right

1:39:45

and so

1:39:46

even if we

1:39:48

attempt to fight

1:39:49

the evolution

1:39:50

of science

1:39:50

I think we're going

1:39:52

to look back

1:39:52

in a decade

1:39:53

and go

1:39:53

I cannot believe

1:39:54

we put people

1:39:55

on petrol chemicals

1:39:56

to solve problems

1:39:57

because we're going

1:39:58

to be able to go in

1:39:59

and turn off

1:39:59

or on a gene

1:40:00

and fix that problem

1:40:01

right

1:40:02

at the cellular level

1:40:04

the biological level

1:40:06

you're going to be able

1:40:06

to fix and remediate

1:40:07

so many of these issues

1:40:09

that's all they're doing

1:40:11

with the bone mineral density

1:40:12

is they're turning on

1:40:13

a gene that tells you

1:40:14

to increase your bone

1:40:15

mineral density

1:40:15

or when you look

1:40:16

at the folostatin

1:40:18

you know

1:40:19

that they're using

1:40:20

in cattle

1:40:20

that's just a gene

1:40:21

signal that tells

1:40:22

your gene

1:40:23

hey turn on

1:40:23

and you're going

1:40:24

to put on muscle

1:40:24

and for a 6 to

1:40:26

I think it's a 6 to 12

1:40:27

month time frame

1:40:28

that folostatin gene

1:40:31

will be turned on

1:40:32

and you'll put on muscle

1:40:33

and then at the end

1:40:35

of that

1:40:35

it gets turned back off

1:40:37

so it's like

1:40:38

temporary turning

1:40:38

on a white light switch

1:40:39

and then that light switch

1:40:41

will eventually

1:40:42

revert back

1:40:42

so this

1:40:43

this

1:40:44

Jamie

1:40:45

bring back up

1:40:46

that thing

1:40:46

with the bone mineral

1:40:47

density

1:40:48

does it prevent you

1:40:50

from being able

1:40:51

to swim

1:40:51

just because you're

1:40:52

heavier

1:40:52

is that the idea

1:40:53

I'm assuming that's what

1:40:54

that's saying

1:40:54

because you're adding

1:40:55

so much weight

1:40:56

and mass

1:40:57

to the body

1:40:57

like think about

1:40:58

french bulldogs

1:40:59

and bulldogs

1:40:59

can't swim

1:41:00

because they're so dense

1:41:02

but pit bulls can swim

1:41:03

yeah pit bulls can

1:41:04

but french bulldogs

1:41:05

and english bulldogs

1:41:06

will drown

1:41:07

really

1:41:08

yeah they don't have

1:41:09

enough arm strength

1:41:10

and muscle mass

1:41:11

they're so dense

1:41:12

and heavy

1:41:13

is that what it is

1:41:13

or is it their legs

1:41:14

are so short

1:41:15

it's both

1:41:15

they don't have

1:41:16

the ability to move

1:41:17

to move enough momentum

1:41:19

of that denseness

1:41:20

of their body composition

1:41:21

because little carl's jacked

1:41:22

you ever see carl

1:41:23

carl is like a little

1:41:25

he hates the water

1:41:25

though he might not

1:41:26

like being in the pool

1:41:27

he's a tank

1:41:28

he's smart

1:41:28

well marshall's like soft

1:41:30

marshall's very soft

1:41:31

he swims like a fish

1:41:32

he loves swimming

1:41:33

that dog just

1:41:35

he could swim for hours

1:41:36

that's so funny

1:41:37

he doesn't have any

1:41:38

yeah my french

1:41:39

he loves water

1:41:39

but he can't swim

1:41:41

so he'll go in the shallow end

1:41:42

but he's smart enough

1:41:43

to not get off the step

1:41:45

like he knows

1:41:46

oh that's interesting

1:41:47

yeah

1:41:47

so I would imagine also

1:41:50

there would be

1:41:51

so what's this

1:41:52

I'm just looking

1:41:53

at the comment

1:41:53

this didn't have

1:41:54

a link or anything

1:41:55

it was literally

1:41:55

just a picture of an x-ray

1:41:56

so like not a lot

1:41:58

of information

1:41:58

to pull off of that

1:41:59

unable to swim

1:42:00

is weird

1:42:01

but I don't even know

1:42:02

who posted it

1:42:02

because it's more

1:42:03

difficult to swim

1:42:04

because you're heavier

1:42:06

because like

1:42:07

my kids can swim

1:42:08

you know

1:42:09

because you know

1:42:10

my daughter

1:42:12

my 15 year old

1:42:13

might weigh 120 pounds

1:42:15

or something like that

1:42:15

150

1:42:16

I weigh like 204

1:42:17

I go in the water

1:42:19

I just sink

1:42:20

I can't float

1:42:22

yeah it's

1:42:22

well you don't have

1:42:23

any body fat either

1:42:23

it's dense

1:42:24

it's all muscle

1:42:25

and bone

1:42:25

it's a struggle

1:42:26

for me to swim

1:42:27

yeah

1:42:27

you know

1:42:28

but I wonder

1:42:29

like if

1:42:31

is it

1:42:31

so if your bones

1:42:33

or have more

1:42:35

or they're more hollow

1:42:37

does that help you swim

1:42:39

because they're more hollow

1:42:40

like does that

1:42:41

aid in swimming

1:42:42

what's so fascinating

1:42:43

to all this to me

1:42:44

is

1:42:44

so then you've got

1:42:45

so getting to meet

1:42:46

all these different

1:42:47

scientists right

1:42:47

you got Ryan

1:42:48

who was working

1:42:49

for DARPA

1:42:50

and then I know

1:42:51

Ian who's been

1:42:52

20 years of

1:42:53

stem cell research

1:42:54

and Ian in his book

1:42:55

talks about

1:42:55

that we share

1:42:56

a common ancestor

1:42:57

and I've covered

1:42:58

this before

1:42:58

but Ian hypothesizes

1:43:00

within our genetics

1:43:02

we share an ancestor

1:43:04

with the eternal jellyfish

1:43:05

we share an ancestor

1:43:07

with the Galapagos tortoise

1:43:08

with the Greenland shark

1:43:09

Greenland sharks

1:43:11

don't develop cancer

1:43:11

they live

1:43:12

500 to 600 years

1:43:14

the jellyfish

1:43:15

lives eternally

1:43:15

all of those

1:43:17

black boxes

1:43:18

are within us

1:43:19

if we can find those

1:43:20

through gene sequencing

1:43:21

and we can identify

1:43:22

which gene is doing that

1:43:24

in the animal kingdom

1:43:25

and cross reference that

1:43:26

to our own genetics

1:43:28

the question then becomes

1:43:29

can you either

1:43:30

insert that gene

1:43:31

into humans

1:43:32

or is that gene available

1:43:34

and can you turn it on

1:43:35

and what's the side effect

1:43:37

to turn it on

1:43:37

so individuals

1:43:39

with unexplained

1:43:41

HBM had an excess

1:43:42

of sinking

1:43:43

when swimming

1:43:44

what is that number

1:43:45

7.1136

1:43:47

what does that mean

1:43:47

adjusted odds ratio

1:43:49

with 95% confidence

1:43:51

mandible

1:43:51

so it says

1:43:52

excess of sinking

1:43:54

when swimming

1:43:55

so it just seems

1:43:56

like it's more difficult

1:43:57

to swim

1:43:57

because you're heavier

1:43:58

yeah you're more dense

1:43:59

it's more difficult

1:44:00

for me to swim

1:44:01

associated dysplasia

1:44:03

skeletal dysplasia

1:44:05

that's not good right

1:44:06

what is this

1:44:09

I'm thinking of

1:44:10

hip dysplasia

1:44:10

harbor an underlying

1:44:12

genetic disorder

1:44:13

affecting bone mass

1:44:14

this was just a study

1:44:15

based off of a high

1:44:16

bone density

1:44:16

this wasn't specific

1:44:17

to that

1:44:18

which just makes sense

1:44:19

that they sink more

1:44:20

this is stuff

1:44:21

that's like

1:44:22

in its infancy

1:44:22

but I just think

1:44:23

it's fascinating

1:44:24

right

1:44:24

well that Brian Shaw

1:44:26

dude

1:44:26

that guy can't swim

1:44:27

there's no fucking way

1:44:28

that guy must sink

1:44:30

like a rock

1:44:30

because didn't he have

1:44:31

like the most insane

1:44:32

bone mineral density

1:44:33

tested

1:44:34

they said his bone

1:44:35

mineral density

1:44:36

is one of 500 million

1:44:38

so there might be

1:44:41

like what

1:44:42

eight people

1:44:43

ten people

1:44:43

on earth

1:44:44

that have that

1:44:45

yeah

1:44:45

that's so crazy

1:44:47

and that

1:44:47

I mean

1:44:48

but that's probably

1:44:49

genetics

1:44:50

and also training

1:44:51

right

1:44:52

he's obviously

1:44:53

a strong man

1:44:53

so he's been

1:44:54

lifting enormous amounts of weight

1:44:55

and there's crazy

1:44:55

so they've done

1:44:56

what is it

1:44:58

Devin Lorette

1:44:58

do you know

1:44:59

yeah sure

1:44:59

arm wrestle

1:45:00

yeah Devin came

1:45:01

into the clinic

1:45:02

he's done his gene

1:45:03

sequencing

1:45:03

and it's crazy

1:45:06

like the guy

1:45:07

has so many genes

1:45:10

that are just

1:45:11

statistically impossible

1:45:13

it's like

1:45:14

was this guy

1:45:14

built in a lab

1:45:15

to arm wrestle

1:45:16

it's crazy

1:45:18

like he has

1:45:19

that same tendon gene

1:45:20

he has the bone

1:45:20

mineral density gene

1:45:21

he has some very

1:45:22

very unique genes

1:45:23

and so part of this

1:45:25

is just like

1:45:26

the knowledge

1:45:27

and the excitement

1:45:28

of what can we do

1:45:29

in the future

1:45:29

I don't know

1:45:30

but today I think

1:45:31

you know

1:45:32

knowing your software

1:45:34

that you're running on

1:45:35

it's crazy to think

1:45:36

that everyone knows

1:45:36

which version

1:45:37

of the iPhone software

1:45:38

they've got

1:45:38

you got a 7 point

1:45:39

whatever

1:45:40

but we don't know

1:45:41

what code

1:45:42

our body's running on

1:45:43

but here's the question

1:45:44

these genes

1:45:45

are inherent

1:45:46

to you from birth

1:45:47

or is anything

1:45:49

a result of training

1:45:51

the genes are inherent

1:45:52

to you at birth

1:45:53

and then you do

1:45:55

have epigenetics

1:45:56

and epigenetics

1:45:56

are impacted

1:45:57

by your body

1:45:59

by activity

1:46:00

right

1:46:00

so you may have

1:46:01

a predisposition

1:46:02

to developing

1:46:05

cancer cells

1:46:05

right

1:46:06

that's unfortunate

1:46:07

but you may have that

1:46:08

but that doesn't mean

1:46:09

definitively

1:46:09

you're going to develop

1:46:10

cancer

1:46:10

it just means

1:46:11

you can now make

1:46:12

lifestyle and behavioral

1:46:13

changes to minimize

1:46:15

so if you have

1:46:16

a predisposition

1:46:17

to that

1:46:17

you probably shouldn't

1:46:18

smoke cigarettes

1:46:18

all day

1:46:19

right

1:46:20

we should probably

1:46:21

try to

1:46:21

if you have

1:46:22

a predisposition

1:46:23

to weak bone

1:46:24

mineral density

1:46:25

right

1:46:25

we should probably

1:46:26

make sure

1:46:26

that we never

1:46:27

let your hormones

1:46:28

drop in your 40s

1:46:29

where you begin

1:46:30

that initial decline

1:46:31

in the cascade effect

1:46:33

this gene mutation

1:46:34

seems to also

1:46:35

have a other side effect

1:46:36

of vision loss

1:46:38

because it causes

1:46:40

some eye vascular issues

1:46:42

interesting

1:46:43

yeah and this is one

1:46:44

this is one example

1:46:45

of genes

1:46:46

that they were looking at

1:46:47

I think at DARPA

1:46:48

and some of these

1:46:48

other projects

1:46:49

these aren't things

1:46:51

being utilized

1:46:51

in medicine today

1:46:52

but this is the direction

1:46:54

of the future

1:46:55

I really do believe

1:46:56

that they're gonna

1:46:57

they're going to solve

1:46:58

a lot of these

1:46:59

genetic traits

1:46:59

and be able to figure

1:47:00

out how to turn

1:47:01

off and on

1:47:02

these traits

1:47:02

right

1:47:03

certain variants

1:47:04

in LRP5 gene

1:47:06

interfere with

1:47:06

eye blood vessel

1:47:08

development

1:47:09

causing familial

1:47:11

exudative

1:47:12

what's that word

1:47:14

can lead to

1:47:15

vision loss

1:47:15

vitro retinopathy

1:47:18

which can lead

1:47:19

to vision loss

1:47:20

mutations can cause

1:47:21

varying clinical

1:47:22

presentations

1:47:23

ranging from

1:47:24

asymptomatic high

1:47:25

bone density

1:47:26

to severe skeletal

1:47:27

fragility

1:47:27

or blindness

1:47:28

whoa

1:47:29

calling that a fever

1:47:30

is pretty tough

1:47:31

yeah

1:47:31

somebody confused

1:47:33

yeah

1:47:33

one of the

1:47:36

man

1:47:36

so one of the other

1:47:37

you said treatments

1:47:38

that we're doing

1:47:38

one of the things

1:47:39

that I think is

1:47:40

the most exciting

1:47:42

thing that I have

1:47:42

come across

1:47:43

and I know

1:47:44

I think you know

1:47:44

where I'm going

1:47:44

with this

1:47:45

in my entire

1:47:46

time in healthcare

1:47:47

is the muse

1:47:49

stem cells

1:47:50

yeah

1:47:51

so I don't know

1:47:52

if you want me

1:47:53

to talk a little bit

1:47:54

about that

1:47:54

so for the listeners

1:47:57

because of you

1:47:59

candidly

1:48:00

I get approached

1:48:00

all the time

1:48:01

from scientists

1:48:02

from doctors

1:48:03

from people going

1:48:03

hey I've got this

1:48:04

thing that's going

1:48:05

to change the world

1:48:06

and I'm like

1:48:06

sure you do

1:48:07

and you just

1:48:08

never know

1:48:08

so I had a company

1:48:10

reach out

1:48:11

and they're like

1:48:11

hey we would love

1:48:12

to meet with you

1:48:13

we have a

1:48:14

sub-phenotype

1:48:14

of stem cell

1:48:15

that we think

1:48:16

is going to

1:48:16

change the world

1:48:17

and so I call

1:48:19

Dr. White

1:48:19

you know

1:48:21

who's my

1:48:22

chief science officer

1:48:23

and I have him

1:48:24

vet these folks

1:48:25

and he's like

1:48:26

man I don't know

1:48:27

it sounds too good

1:48:27

to be true

1:48:28

they're like

1:48:29

we would love

1:48:29

for you guys

1:48:30

to fly to Japan

1:48:31

meet with Mari

1:48:32

does wanna

1:48:33

and hear her lectures

1:48:36

and tour the lab

1:48:37

and kind of see

1:48:38

what she's been doing

1:48:39

since 2010

1:48:40

we reviewed all the research

1:48:42

all the data

1:48:43

all the literature

1:48:44

and it was mind boggling

1:48:46

so Ian and I hopped on a plane

1:48:48

and went to Japan

1:48:49

back in September

1:48:50

and sat down with Mari

1:48:52

and she was gracious enough

1:48:54

to break down

1:48:55

all of her research

1:48:56

answer Ian's questions

1:48:58

and I'm gonna be clear

1:49:00

like we went there

1:49:01

to debunk this shit

1:49:02

we thought there's no way

1:49:04

that this is what

1:49:05

she's presenting

1:49:06

it's just

1:49:06

it just seems

1:49:08

too good to be true

1:49:09

and after sitting

1:49:11

through those lectures

1:49:12

and Mari

1:49:13

enlightening us

1:49:15

on all of her research

1:49:16

and what she's seen

1:49:17

I left there with Ian

1:49:19

and he looked at me

1:49:19

and was like

1:49:20

this

1:49:20

if this is real

1:49:22

this is going to change

1:49:23

everything

1:49:24

in the regenerative space

1:49:26

and Ian I think

1:49:27

won regenerative scientist

1:49:28

of the year

1:49:29

last year

1:49:30

in North America

1:49:30

he won some

1:49:32

a big award

1:49:33

for this space

1:49:35

and Ian

1:49:35

is a stem cell scientist

1:49:37

and

1:49:38

but these Muse

1:49:39

stem cells

1:49:40

are such a rare

1:49:41

subset phenotype

1:49:43

of stem cell

1:49:43

and so

1:49:44

the best way

1:49:45

to explain it is

1:49:46

to try and break it down

1:49:49

in like layman's terms

1:49:50

is Muse

1:49:51

stands for

1:49:52

multi-lineage

1:49:53

and

1:49:54

the SE

1:49:55

of Muse

1:49:55

stands for

1:49:56

stress

1:49:57

enduring

1:49:58

so

1:49:58

what does that mean

1:49:59

in like real world talk

1:50:01

Mari in her book

1:50:03

where she writes about

1:50:04

these cells

1:50:04

and how she discovered them

1:50:06

she was in the lab

1:50:07

she had

1:50:07

she kept coming across

1:50:09

this small

1:50:09

outlier subset

1:50:11

of stem cells

1:50:11

that appeared to have

1:50:13

a lot of unique qualities

1:50:14

but they were less than

1:50:15

2% of stem cells

1:50:17

so

1:50:17

stem cells

1:50:18

that are already

1:50:18

a very minute amount

1:50:19

of the cells in our body

1:50:21

have a subset phenotype

1:50:22

called Muse

1:50:23

she had to rush out

1:50:25

to a dinner

1:50:26

where in Japan

1:50:27

where she ended up

1:50:28

eating sushi

1:50:28

and having sake

1:50:29

and forgot

1:50:30

to put the cells

1:50:31

back

1:50:32

take them off

1:50:32

the petri dish

1:50:33

and put them back

1:50:34

in cryopreserve

1:50:35

she thought she'd go in

1:50:36

the next day

1:50:36

and everything would be dead

1:50:37

when she went in

1:50:38

because the cells

1:50:39

don't last overnight

1:50:40

she goes in the next day

1:50:42

and to her surprise

1:50:42

all of those subset

1:50:44

phenotype of cells

1:50:45

were still alive

1:50:45

a large majority

1:50:46

of them were still alive

1:50:47

and she thought

1:50:48

that can't be possible

1:50:49

and that was in 2010

1:50:51

and that's what began

1:50:52

her research

1:50:53

into what are Muse

1:50:54

and so

1:50:55

without getting

1:50:56

too in the weeds

1:50:57

I'd love to like

1:50:58

break down

1:50:59

what it is

1:51:00

what makes it unique

1:51:01

and why it's so promising

1:51:02

if you're game

1:51:04

because it's super cool

1:51:05

first and foremost

1:51:07

in medicine

1:51:08

they say

1:51:08

do no harm

1:51:10

right

1:51:11

and so

1:51:11

when we're lobbying

1:51:12

and trying to educate

1:51:14

these politicians

1:51:15

and these regulators

1:51:16

on the safety profile

1:51:17

of traditional MSCs

1:51:18

traditional stem cells

1:51:20

are extremely safe

1:51:21

and I've said this

1:51:23

on your podcast before

1:51:24

Dr. Kaplan

1:51:26

who discovered

1:51:27

traditional MSCs

1:51:28

in an open letter

1:51:28

to the scientific community

1:51:30

apologized

1:51:30

and said

1:51:31

I should have never

1:51:32

called them stem cells

1:51:33

because the problem

1:51:34

with these cells

1:51:34

is they don't differentiate

1:51:36

they don't become anything

1:51:37

that only happens

1:51:38

in a petri dish

1:51:39

but in the body

1:51:40

they just signal

1:51:41

to damage

1:51:42

and then they transfer

1:51:44

their mitochondria

1:51:44

and they temporarily

1:51:45

give your body

1:51:46

an environment

1:51:48

to heal faster

1:51:49

and to recover

1:51:49

so they aren't

1:51:51

truly regenerative

1:51:52

in that they don't

1:51:52

become a tendon

1:51:54

they don't become

1:51:55

a neuron

1:51:55

and there's pros

1:51:58

and cons to that

1:51:58

the pros are

1:51:59

they don't become

1:52:00

a cancer cell

1:52:01

and that's the

1:52:02

concern

1:52:02

with pluripotency

1:52:04

and so the holy grail

1:52:06

of what people

1:52:07

have always looked for

1:52:08

with stem cells

1:52:08

were could we

1:52:09

for lack of a better term

1:52:11

fuck with these cells

1:52:12

enough in a petri dish

1:52:13

to create pluripotency

1:52:15

where they can

1:52:15

become something

1:52:16

but prevent

1:52:17

tumorigenic behavior

1:52:19

where they don't

1:52:20

become a tumor

1:52:20

or don't become

1:52:21

a cancer

1:52:21

lo and behold

1:52:23

in 2010

1:52:24

what Mari discovered

1:52:26

was this ultra resilient

1:52:28

subset of stem cell

1:52:29

that holds

1:52:30

those exact traits

1:52:32

it was in us

1:52:33

all along

1:52:33

it's always been in us

1:52:35

this wasn't created

1:52:36

in a petri dish

1:52:37

this is biology

1:52:39

this is the

1:52:41

stem cell answer

1:52:42

that has eluded

1:52:44

scientists

1:52:44

for decades

1:52:46

and it is so exciting

1:52:48

because the multi-lineage

1:52:50

what does that mean

1:52:51

multi-lineage

1:52:52

just means

1:52:53

these are pluripotent cells

1:52:54

pluripotent multi-lineage

1:52:56

is a bunch of

1:52:56

fancy science talk

1:52:57

for they can become

1:52:59

anything

1:53:00

so the way I explain

1:53:02

that is

1:53:02

you and I talked

1:53:03

about this years ago

1:53:04

orthopedic surgeons

1:53:05

would go

1:53:06

you know I use

1:53:07

bone marrow stem cells

1:53:08

and I don't really

1:53:09

get good results

1:53:10

and I think that

1:53:11

you can't get

1:53:12

real stem cells

1:53:13

because those cells

1:53:14

have an identity

1:53:15

and when you take

1:53:16

bone marrow

1:53:16

the cells have already

1:53:18

become a bone marrow cell

1:53:19

and they're not going

1:53:20

to differentiate

1:53:20

and become something

1:53:21

so heretofore

1:53:22

they can't heal

1:53:23

there's some truth to that

1:53:25

they couldn't

1:53:26

they could just

1:53:27

help regenerate

1:53:28

or help

1:53:29

I guess

1:53:30

optimize your body's healing

1:53:31

through bringing down

1:53:32

inflammation

1:53:32

and potentially

1:53:34

transferring mitochondria

1:53:35

into your old

1:53:36

tired weary cell

1:53:36

cells

1:53:37

where these cells

1:53:38

are fundamentally

1:53:39

different

1:53:39

is think of it

1:53:41

like a kindergartner

1:53:42

a kindergartner

1:53:43

can be anything

1:53:44

the world is that

1:53:46

child's oyster

1:53:47

if they want to grow up

1:53:48

and be a doctor

1:53:49

they can be a doctor

1:53:50

if they want to grow up

1:53:50

and be an astronaut

1:53:51

they can be an astronaut

1:53:52

the traditional cells

1:53:54

that doctors

1:53:55

and clinicians

1:53:56

have been using

1:53:56

in America

1:53:57

they're already grown up

1:53:59

they've already chose

1:54:00

their identity

1:54:00

they already went

1:54:01

to med school

1:54:02

and they decided

1:54:02

they're a doctor

1:54:03

you can't put those

1:54:04

in the body

1:54:04

and have them

1:54:05

become something

1:54:06

because they've already

1:54:07

developed their identity

1:54:08

their phenotype

1:54:09

these cells

1:54:10

will literally

1:54:11

go into the body

1:54:12

and take on

1:54:13

the phenotype

1:54:14

of any damaged cell

1:54:16

what is so amazing

1:54:19

and crucial about that

1:54:20

to understand is

1:54:21

if they come across

1:54:22

a torn tendon cell

1:54:24

they become that tendon cell

1:54:26

if it's a bone marrow cell

1:54:27

they become a bone marrow

1:54:28

if it's a neuron

1:54:29

they can become a neuron

1:54:31

and the process

1:54:33

that they do it through

1:54:34

is also pretty fascinating

1:54:35

it's a commonly known process

1:54:37

but phagocytosis

1:54:38

don't say it three times fast

1:54:40

it can get cancelled

1:54:41

but like

1:54:42

phagocytosis

1:54:43

essentially

1:54:44

and even in that layman's term

1:54:46

is like

1:54:46

think of it like a pac-man

1:54:47

this is how Mari described it to me

1:54:49

because she knows I'm an idiot

1:54:51

and she's like trying to break it down

1:54:52

in a way I can digest

1:54:53

she's like

1:54:54

I want you to think of a pac-man

1:54:56

think of a damaged cell

1:54:57

like a neuron

1:54:58

this pac-man is going to go up

1:54:59

gobble up that neuron

1:55:01

through the process of phagocytosis

1:55:02

and take on

1:55:03

all of the characteristics

1:55:05

and code

1:55:06

of that

1:55:07

cell

1:55:08

meaning

1:55:09

it will become

1:55:10

a young

1:55:10

healthy

1:55:11

version

1:55:12

of the damaged cell

1:55:14

so

1:55:14

one

1:55:15

these cells

1:55:17

are extremely safe

1:55:18

in that

1:55:19

they're non-tumorgenic

1:55:20

in studies

1:55:22

these cells

1:55:24

had

1:55:25

no

1:55:25

never became tumors

1:55:27

in any of the studies

1:55:28

that are ever done

1:55:29

furthermore

1:55:30

they treated mice

1:55:31

that had pre-existing cancer

1:55:33

they did not only

1:55:34

not exasperate

1:55:36

the tumors

1:55:36

in many of the studies

1:55:38

the tumors shrunk

1:55:39

and I'm not here to say like

1:55:40

it's going to cure cancer

1:55:42

or anything like that

1:55:42

the message is

1:55:43

traditional MSCs

1:55:46

are already extremely safe

1:55:48

and these MSCs

1:55:49

appear to be

1:55:50

even

1:55:51

as safe

1:55:52

if not more safe

1:55:54

and the only

1:55:55

knock on traditional MSCs

1:55:57

in real world application

1:55:58

when utilized appropriately

1:56:00

is

1:56:01

they have an

1:56:03

immunomodulatory

1:56:04

modulatory

1:56:05

immuno

1:56:06

immunity response

1:56:08

essentially where

1:56:09

10 to 15% of people

1:56:10

will get flu-like symptoms

1:56:11

and that's with traditional MSCs

1:56:13

which is a very low

1:56:15

safety profile

1:56:16

what you saw

1:56:17

like effective safety profile

1:56:19

what you saw

1:56:20

with the muse cells

1:56:21

in trials

1:56:21

is 0%

1:56:23

literally right now

1:56:25

nobody's even getting

1:56:26

flu-like symptoms

1:56:27

and it's because

1:56:28

these muse cells

1:56:29

go above and beyond

1:56:31

immuno

1:56:33

like the ability to

1:56:34

navigate your immune system

1:56:36

and go into

1:56:36

immunomodulating

1:56:38

your immune system

1:56:39

so what do I mean by that?

1:56:40

Mari did a study

1:56:42

where she took mice

1:56:43

sutured in human livers

1:56:44

into the mice's liver

1:56:46

the mice should reject that

1:56:47

and die

1:56:48

they implant

1:56:49

mu cells in

1:56:50

and the liver

1:56:51

will accept

1:56:52

the human liver

1:56:53

for a period of time

1:56:54

they eventually

1:56:54

rejected the liver

1:56:55

but it's able

1:56:56

to immunomodulate

1:56:58

so think about this

1:56:58

for

1:56:59

a simple way

1:57:01

to explain it

1:57:01

is the whole process

1:57:02

I broke down before

1:57:03

like when a mother's pregnant

1:57:04

that baby

1:57:05

is technically

1:57:06

a foreign body

1:57:07

in the mother

1:57:08

so what in science

1:57:09

stops that mother's body

1:57:10

from rejecting

1:57:11

and killing the baby

1:57:12

and her immune system

1:57:13

attacking the baby

1:57:14

the answer

1:57:16

is MSCs

1:57:16

the answer is

1:57:18

the juices of life

1:57:21

that allow that

1:57:22

mother's system

1:57:23

to immunomodulate

1:57:24

and not turn on the baby

1:57:26

so not only does it

1:57:28

build up the mom's immune system

1:57:30

and helps the mom

1:57:31

reduce inflammation

1:57:32

reduce

1:57:33

like her risk of

1:57:34

chronic disease

1:57:35

and all mortality cause

1:57:37

is at an all-time low

1:57:38

while pregnant

1:57:39

the risk of cancer

1:57:40

is at an all-time low

1:57:41

while pregnant

1:57:42

all of this goes back

1:57:43

to MSCs

1:57:45

and now we believe

1:57:46

potentially muse cells

1:57:48

and so

1:57:49

they're safe

1:57:50

they're non-tumorgenic

1:57:51

they immunomodulate

1:57:53

meaning your body's

1:57:54

not going to reject

1:57:55

these cells

1:57:55

you're not going to

1:57:56

have a huge risk

1:57:56

what's crazy

1:57:57

is they're already

1:57:57

using it in plastic surgery

1:57:59

this is what I was talking

1:58:00

they would take

1:58:01

historically

1:58:03

instead of

1:58:03

women were using fillers

1:58:05

and the reason

1:58:05

they used fillers

1:58:06

instead of fat

1:58:06

is fat lacks angiogenesis

1:58:08

and those fat cells die

1:58:10

and a lot of times

1:58:11

the success rate's

1:58:12

not as high

1:58:12

so what they're doing

1:58:14

in Dubai

1:58:15

and these other nations

1:58:16

is they're using muse

1:58:17

when they do

1:58:18

a reconstructive surgery

1:58:19

to reduce the risk

1:58:21

that you have

1:58:21

an immune response

1:58:22

that rejects

1:58:23

the fat tissue

1:58:24

so it encourages

1:58:25

the body

1:58:26

to accept that tissue

1:58:27

and then helps

1:58:28

those cells

1:58:29

build themselves

1:58:30

back into your system

1:58:31

and immunoregulate

1:58:33

so think about it

1:58:35

for the future

1:58:35

of like organ transplants

1:58:36

what this could mean

1:58:38

if the science holds

1:58:40

in practice

1:58:40

of what they're seeing

1:58:42

but for the sake

1:58:43

of conversation today

1:58:44

the point of saying

1:58:45

all that is

1:58:45

extremely safe

1:58:47

no risk of tumors

1:58:49

non-tumorgenic

1:58:51

immunomodulating

1:58:53

meaning your body's

1:58:54

not going to turn on it

1:58:55

it's not going to cause

1:58:56

any sort of

1:58:56

inflammatory response

1:58:57

or flu-like symptoms

1:58:58

so one of the safest

1:59:00

versions of stem cells

1:59:01

we've ever seen

1:59:02

and the traditional cells

1:59:03

are extremely safe

1:59:04

themselves

1:59:05

and then you get

1:59:06

into the pluripotency

1:59:07

I mean this is

1:59:08

the first cell

1:59:09

other than the cells

1:59:12

that have been altered

1:59:13

that can truly

1:59:15

become something

1:59:16

and then the fourth

1:59:18

and final thing

1:59:19

that's really amazing

1:59:20

about these cells

1:59:21

is their honing abilities

1:59:23

so traditional MSCs

1:59:25

what we've been using

1:59:26

at WasteWell

1:59:27

for the last five years

1:59:28

even with the great success

1:59:32

we've had

1:59:32

they literally have

1:59:34

a 3 to 5%

1:59:35

engraftment rate

1:59:36

meaning 3 to 5%

1:59:38

of those cells

1:59:39

make it to the site

1:59:40

of damage

1:59:41

and begin the healing process

1:59:43

in the site of damage

1:59:44

and think about the results

1:59:45

we've gotten

1:59:46

now look at Muse

1:59:48

Muse have a 15 to 30%

1:59:52

engraftment rate

1:59:53

Muse are literally

1:59:55

half the size

1:59:56

of traditional MSCs

1:59:57

and they have the ability

1:59:58

when administered

1:59:59

intravenously

2:00:00

to pass the lungs

2:00:02

and make it to the site

2:00:04

of inflammation

2:00:04

and damage

2:00:05

they hone in

2:00:06

at a much stronger rate

2:00:08

than traditional MSCs

2:00:10

so the way to think of it

2:00:11

is like

2:00:12

you're taking

2:00:13

a heat-seeking missile

2:00:14

that's able to find

2:00:15

exactly where the

2:00:16

S1P

2:00:17

S1 inflammation

2:00:20

damaged cell

2:00:21

is the signal

2:00:22

that a cell sends out

2:00:23

hey I'm damaged

2:00:24

these Muse cells

2:00:25

will navigate

2:00:26

straight to those

2:00:27

damaged cells

2:00:28

through phagocytosis

2:00:29

absorb that cell

2:00:31

take on its phenotype

2:00:32

and be a young

2:00:33

healthy vibrant

2:00:34

version of that cell

2:00:35

and all of this

2:00:37

occurs within three days

2:00:38

so that's why

2:00:40

you're seeing

2:00:41

such crazy results

2:00:42

in Dubai

2:00:43

and overseas

2:00:45

and these are the

2:00:46

treatments that are

2:00:47

coming into the U.S.

2:00:48

that are going to be

2:00:49

manufactured here

2:00:50

on U.S. soil

2:00:51

and utilized

2:00:51

in states right now

2:00:53

like Florida

2:00:53

Texas

2:00:54

Arizona

2:00:55

and the states

2:00:56

that have built

2:00:56

pathways that make

2:00:57

this approachable

2:00:58

for people

2:00:58

the hope is

2:01:00

that we can build

2:01:01

a regulatory pathway

2:01:02

at the federal level

2:01:03

that will allow

2:01:04

accessibility too

2:01:05

because

2:01:05

what is definitively

2:01:07

clear is these

2:01:08

treatments

2:01:09

even the old MSCs

2:01:10

and purified amnion

2:01:12

and Wharton's jelly

2:01:13

and all those things

2:01:14

there's no arguing

2:01:15

that they're extremely safe

2:01:16

I mean there's 30

2:01:18

40 years of data

2:01:19

on these products

2:01:20

they are safe

2:01:21

they are available

2:01:22

in nature

2:01:22

they occur naturally

2:01:23

the question is

2:01:25

how efficacious are they

2:01:26

what disease states

2:01:28

can they help with

2:01:28

and how much

2:01:29

can they move the needle

2:01:30

and that's where

2:01:31

this gets tricky

2:01:32

because the FDA

2:01:33

doesn't want people

2:01:33

out there making claims

2:01:34

and I understand that

2:01:35

because there's so many

2:01:36

people who are

2:01:37

snake oil salesmen

2:01:38

and my thing is

2:01:39

I'm not here to make

2:01:40

a claim

2:01:41

I'm just here to say

2:01:41

accessibility is important

2:01:43

because for the people

2:01:45

who don't have

2:01:46

any more lifeline left

2:01:48

who knows what this

2:01:50

could do for them

2:01:50

for the patients

2:01:51

you know

2:01:52

battling some sort

2:01:53

of neurocognitive issue

2:01:55

you know

2:01:56

these cells are able

2:01:57

to pierce into the midbrain

2:01:58

I mean

2:01:59

and I have all these

2:02:00

Jamie

2:02:00

a bunch of these studies

2:02:01

I have listed on

2:02:02

Ways to Well's website

2:02:03

just so I'm not

2:02:05

throwing random stuff

2:02:06

out there

2:02:07

I think I listed

2:02:08

seven or eight

2:02:09

of Mari Dazawa's

2:02:11

studies

2:02:12

that back

2:02:14

everything that I'm saying

2:02:15

but the premise is

2:02:17

you know

2:02:17

the future's bright

2:02:19

and I think that

2:02:20

Muse will be

2:02:20

an integral part

2:02:21

of what we see

2:02:22

here in the United States

2:02:23

in the future

2:02:24

of biologics

2:02:25

when we're talking

2:02:26

about genes

2:02:27

these obviously

2:02:28

are in the body

2:02:29

these cells

2:02:31

is it

2:02:31

is there a potential future

2:02:33

where they could just

2:02:34

turn these things on

2:02:36

and not have to add

2:02:37

exogenous

2:02:38

stem cells

2:02:40

so here's

2:02:41

the problem is

2:02:42

you have a precipitous

2:02:43

decline as you age

2:02:44

right

2:02:45

and so just like

2:02:45

what we're seeing

2:02:46

with peptides

2:02:47

you have a certain

2:02:47

amount of these

2:02:48

and as you age

2:02:49

they appear to decline

2:02:50

the other thing

2:02:52

that this is a crazy

2:02:53

so you've got

2:02:54

this scientist

2:02:55

Dr. Dominic Deutscher

2:02:57

out of Germany

2:02:58

brilliant guy

2:02:59

Stanford trained

2:03:00

went to Stanford

2:03:02

did research at Stanford

2:03:03

went to Harvard

2:03:04

University of Munich

2:03:06

crazy background

2:03:08

14 years of stem cell research

2:03:10

he catches wind

2:03:12

of what Mari's doing

2:03:13

and he had been

2:03:14

working on a study

2:03:15

going there appears

2:03:16

to be

2:03:17

this weird subset

2:03:18

of stem cells

2:03:19

that I can't figure out

2:03:21

what they're doing

2:03:21

but they're not there

2:03:23

in diabetic patients

2:03:24

when I look at patients

2:03:26

that are diabetic

2:03:26

they don't have

2:03:28

this subset

2:03:29

so what is this subset

2:03:31

and what is it doing

2:03:32

but he couldn't figure it out

2:03:34

he was on the cusp

2:03:36

of figuring it out

2:03:37

and then he meets Mari

2:03:38

and goes

2:03:39

oh my god

2:03:40

you literally figured out

2:03:42

what the fuck

2:03:42

I've been trying to solve

2:03:43

for the last 14 years

2:03:45

the reason is

2:03:46

these patients are diabetic

2:03:48

and their system

2:03:49

is so chronically riddled

2:03:51

with inflammation

2:03:53

and all these issues

2:03:54

the environment

2:03:56

or whatever it is

2:03:57

their lifestyle

2:03:57

caused the decline

2:03:59

and basically

2:04:00

the end of these cells

2:04:02

all their ability to heal

2:04:04

was used up

2:04:05

is that part of the reason

2:04:07

other than just blood flow

2:04:08

and the other challenges

2:04:09

of diabetics

2:04:10

it could be

2:04:12

one of the under

2:04:13

under causing

2:04:15

attributes

2:04:16

that are causing

2:04:17

these diabetic patients

2:04:18

to heal poorly

2:04:19

to be chronically inflamed

2:04:21

so it could be part

2:04:23

of that equation

2:04:24

but what's fascinating

2:04:25

is it also declines

2:04:26

as we age

2:04:27

so you're going to see

2:04:28

way more of these

2:04:29

at birth

2:04:29

way less of these

2:04:30

in your 30s

2:04:31

probably non-existent

2:04:33

by the time you're

2:04:34

in your 40s and 50s

2:04:35

and so if we can

2:04:36

take these cells

2:04:37

these goodies of life

2:04:38

and we can administer

2:04:40

them proactively

2:04:42

and preventatively

2:04:43

they even did

2:04:45

mitochondrial testing

2:04:46

I don't know if that

2:04:46

study is released yet

2:04:47

if it is I'll add it

2:04:49

to the website

2:04:50

I'll find out from Mari

2:04:51

but they did a

2:04:52

mitochondrial function test

2:04:54

one IV bag administration

2:04:55

took one and a half years

2:04:57

off the mitochondrial age

2:04:58

whoa

2:04:59

and so I'm not saying

2:05:00

that it reverses aging

2:05:02

but in these studies

2:05:03

it appears to have

2:05:03

extreme mitochondrial

2:05:05

benefits

2:05:05

which would

2:05:07

logic to reason

2:05:09

as to why

2:05:10

we're seeing such

2:05:10

phenomenal results

2:05:11

with these treatments

2:05:12

and where even

2:05:14

and I'm still a huge

2:05:15

proponent of all

2:05:16

of the traditional

2:05:17

stuff we've been using

2:05:18

we've seen miraculous

2:05:19

results

2:05:20

with all of these

2:05:22

different modalities

2:05:22

but I look at Muse

2:05:23

and go

2:05:24

this is the holy grail

2:05:26

of what we've been

2:05:27

trying to find

2:05:28

and Mari did it

2:05:29

like she found it

2:05:30

she discovered it

2:05:31

in 2010

2:05:32

they started using it

2:05:34

in human patients

2:05:34

in 2019

2:05:35

these products

2:05:37

are being used

2:05:38

every day

2:05:38

in Dubai

2:05:39

and overseas

2:05:41

people are flying

2:05:42

over there

2:05:42

and paying

2:05:43

boo-koo dollars

2:05:44

to these clinics

2:05:46

to get treatments

2:05:46

with Muse cells

2:05:47

in fact

2:05:49

one of the sheiks

2:05:50

of United Arab Emirates

2:05:51

or one of those

2:05:51

his son got in a car wreck

2:05:53

he literally was

2:05:55

in the hospital

2:05:55

they

2:05:56

this is a true story

2:05:57

they said

2:05:58

he's done

2:05:59

pull the plug

2:06:00

harvest his organs

2:06:01

Dominic

2:06:04

was able to get

2:06:04

a hold of the hospital

2:06:05

the German scientist

2:06:06

and say

2:06:07

hold on

2:06:07

can you guys

2:06:08

do a call

2:06:08

with Mari

2:06:09

I may have a solution

2:06:10

they treated

2:06:12

a kid who had been

2:06:13

comatose

2:06:14

non-responsive

2:06:15

take his organs

2:06:18

like he's done

2:06:19

the neurologists

2:06:20

are like he's done

2:06:21

there is no brain

2:06:22

here anymore

2:06:23

they treat this kid

2:06:25

with intravenous

2:06:25

Muse cells

2:06:26

and his brain

2:06:27

function has come back

2:06:28

he's not talking

2:06:30

but he's responding

2:06:31

to his mother

2:06:32

he's moving his hands

2:06:33

they're no longer

2:06:34

looking to harvest

2:06:35

his organs

2:06:35

and this is a

2:06:36

catastrophic example

2:06:38

but in a more

2:06:39

real world

2:06:40

relevant example

2:06:41

is in Japan

2:06:42

they used it

2:06:43

with children

2:06:45

who were born

2:06:46

with encephalitis

2:06:47

and what they saw

2:06:48

is

2:06:49

these children

2:06:51

who are left

2:06:52

untreated

2:06:53

will definitively

2:06:54

have

2:06:55

neurocognitive

2:06:56

issues

2:06:57

and defects

2:06:58

mental retardation

2:07:00

the children

2:07:01

treated with Muse

2:07:02

within 8 days

2:07:04

of birth

2:07:04

all of those

2:07:05

children had

2:07:06

normal brain function

2:07:07

all of them

2:07:09

and so

2:07:09

the studies

2:07:10

beyond that

2:07:11

and then you get

2:07:12

into

2:07:12

what they saw

2:07:13

in hearts

2:07:14

what they saw

2:07:15

in myocardial

2:07:16

infarctions

2:07:17

like you just

2:07:18

go down the list

2:07:18

and there's so

2:07:20

much promising data

2:07:21

and there's

2:07:23

a decade

2:07:23

worth of it

2:07:24

it just

2:07:25

hasn't made it

2:07:26

into the US

2:07:27

yet

2:07:27

and these

2:07:28

are technologies

2:07:29

and science

2:07:30

and modalities

2:07:31

that are

2:07:32

going to be

2:07:33

adopted

2:07:34

in the near future

2:07:36

at minimal

2:07:36

at the state level

2:07:37

and then hopefully

2:07:38

at the federal level

2:07:39

because

2:07:40

they're already

2:07:41

looking

2:07:41

we know

2:07:42

like I said

2:07:43

Secretary Kennedy

2:07:43

is looking to

2:07:44

open the regulatory

2:07:45

pathway

2:07:46

for stem cells

2:07:47

and mu's

2:07:48

are just a subset

2:07:50

of that same class

2:07:51

but an even safer

2:07:53

more efficacious

2:07:54

version from what

2:07:55

we're seeing

2:07:55

in all of the trials

2:07:56

and what's so exciting

2:07:57

is that

2:07:58

as more research

2:07:59

develops

2:08:00

more of these things

2:08:01

are going to emerge

2:08:02

yep

2:08:03

they're going to keep

2:08:04

the gene therapies

2:08:05

mu's cells

2:08:06

it's going to continue

2:08:07

to compound

2:08:07

well and then you've got

2:08:09

guys like Ryan

2:08:10

who go

2:08:10

if you could take

2:08:12

a mu's cell

2:08:13

and a cell

2:08:14

that could be anything

2:08:15

right

2:08:16

and it already has

2:08:17

it's ready to learn

2:08:18

what if you can

2:08:19

take a mu's cell

2:08:20

and you can teach it

2:08:21

to be exactly

2:08:22

what you want it to be

2:08:23

and then you administer

2:08:24

that cell into the body

2:08:25

but you've already

2:08:26

given it its commands

2:08:27

you've already taught it

2:08:28

that it wants to be

2:08:28

a doctor

2:08:29

right

2:08:30

it wants to be

2:08:30

whatever it is

2:08:31

maybe you make sure

2:08:32

that it's a neuron

2:08:33

again I'm way over

2:08:36

my skis on this part

2:08:37

because I'm a business guy

2:08:38

I'm just breaking down

2:08:39

what these scientists

2:08:41

are saying

2:08:41

and all of it

2:08:42

is exciting

2:08:44

and promising

2:08:44

to me

2:08:45

because again

2:08:46

we've had such

2:08:47

phenomenal results

2:08:49

with traditional

2:08:50

MSCs

2:08:51

you know

2:08:51

with traditional

2:08:52

and all mu's are

2:08:53

are this subset

2:08:54

phenotype

2:08:55

of super soldier cell

2:08:57

they're more resilient

2:08:58

so the second part

2:09:00

of mu's is

2:09:00

stress enduring

2:09:01

so what the whole point

2:09:03

is Mari has a chapter

2:09:04

in her book

2:09:05

called

2:09:05

sake and science

2:09:07

because

2:09:08

through drinking sake

2:09:09

she realized

2:09:10

that there was

2:09:12

an element

2:09:12

of the science

2:09:13

behind this

2:09:13

that she would

2:09:14

have never uncovered

2:09:14

had she not gone

2:09:15

to that dinner

2:09:16

she would have

2:09:17

never realized

2:09:17

that these cells

2:09:19

appear to be

2:09:20

ultra resilient

2:09:21

they can ship

2:09:22

these cells

2:09:23

at room temperature

2:09:24

and they're viable

2:09:25

for weeks

2:09:26

whereas traditional

2:09:27

cells

2:09:27

we've got to keep

2:09:28

cryopreserved

2:09:29

and ship on dry ice

2:09:31

so from an administration

2:09:33

standpoint

2:09:33

from a logistical

2:09:34

standpoint

2:09:35

from an efficacy

2:09:36

standpoint

2:09:37

from a safety

2:09:38

standpoint

2:09:38

all of this

2:09:40

could be so

2:09:41

game changer

2:09:41

so then the next

2:09:42

question just becomes

2:09:43

how do we build

2:09:44

a regulatory pathway

2:09:45

in this country

2:09:47

that allows

2:09:48

accessibility

2:09:48

so that Americans

2:09:50

aren't having to go

2:09:51

to other nations

2:09:52

and the states

2:09:53

some of the states

2:09:54

are doing it

2:09:54

but ideally

2:09:56

it would be optimal

2:09:57

to work

2:09:58

with the federal government

2:09:59

to build those

2:10:00

same pathways

2:10:01

at the federal level

2:10:02

now that the states

2:10:04

have already jumped

2:10:04

on board

2:10:05

god that's so fascinating

2:10:06

such a cool time

2:10:08

dude it's awesome

2:10:09

I'm telling you

2:10:10

and the stuff

2:10:11

it's hard because

2:10:12

again I'm not a clinician

2:10:14

I don't ever

2:10:15

I'm not

2:10:15

I don't want to make claims

2:10:16

I don't want it to be

2:10:17

I am very excited

2:10:19

about this

2:10:19

but I want to temper

2:10:20

my excitement

2:10:21

because I have to be

2:10:22

cautious to say

2:10:23

I don't want to give

2:10:24

people false hope

2:10:25

you know

2:10:26

we don't know

2:10:27

the science is very early

2:10:29

but it is very promising

2:10:30

on a lot of different things

2:10:31

and we've already had

2:10:33

immense success

2:10:33

on orthopedic injuries

2:10:35

knees, shoulders, elbows

2:10:36

using traditional MSCs

2:10:38

that can't differentiate

2:10:39

right

2:10:40

they're just transferring

2:10:41

mitochondria

2:10:42

and temporarily

2:10:43

putting your body

2:10:43

in a position to heal

2:10:44

these mu cells

2:10:46

differentiate

2:10:47

so they literally

2:10:49

are regenerative cells

2:10:50

that become the broken cell

2:10:52

that allow your body

2:10:53

to heal

2:10:54

I mean

2:10:56

and what we do with that

2:10:57

and what the future holds

2:10:58

with that

2:10:59

the sky's the limit

2:11:00

wow

2:11:02

that's amazing

2:11:04

and that's where I just think

2:11:05

eventually we're going to get

2:11:06

to a point where it's like

2:11:07

did we really prescribe

2:11:08

everyone petrochemical drugs

2:11:10

to fix problems

2:11:12

because the genetic side

2:11:13

of the world

2:11:14

and the stem cell side

2:11:15

of the world

2:11:15

and the biologic side

2:11:16

of the world

2:11:17

and all of these things

2:11:18

and then you break in

2:11:19

the large language model side

2:11:21

and wearables

2:11:21

and the ability

2:11:22

to track in real time

2:11:24

but also this is where

2:11:25

you're going to find

2:11:26

the resistance

2:11:26

because there's so much

2:11:27

money in the petrochemical drugs

2:11:29

yeah

2:11:29

and this is what's challenging

2:11:31

with the stem cell stuff

2:11:32

like if they don't work

2:11:36

people are not going to spend

2:11:38

their hard-earned paycheck

2:11:39

right

2:11:39

and that's the challenge

2:11:41

like I understand

2:11:42

the FDA stance

2:11:43

on safety

2:11:44

and again

2:11:45

the historic FDA stance

2:11:46

on not even this new administration

2:11:48

this new administration

2:11:48

has made it clear

2:11:50

their plan is

2:11:51

to open up

2:11:51

the regulatory pathways

2:11:52

on peptides

2:11:53

and stem cells

2:11:54

and cash pay products

2:11:55

and to figure out a pathway

2:11:57

that makes sense

2:11:58

for the American people

2:12:00

while still honoring

2:12:02

the safety and integrity

2:12:03

of what they're trying

2:12:04

to implement

2:12:05

on a grander scale

2:12:07

but do we need

2:12:09

to go through

2:12:10

the level

2:12:11

of rigorous

2:12:12

you know

2:12:14

multi-billion dollar

2:12:15

process on something

2:12:16

that can't really

2:12:17

be patented

2:12:18

or if it's safe

2:12:20

and the safety profile

2:12:21

is proven

2:12:22

and it's readily available

2:12:23

in nature

2:12:23

does it make sense

2:12:25

to grandfather

2:12:26

these treatments in

2:12:27

and to allow patients

2:12:28

compassionate use

2:12:29

right

2:12:29

if you're battling

2:12:30

a chronic disease

2:12:31

and you're going to die

2:12:32

what is the harm

2:12:34

in seeing if this can help

2:12:36

if you're battling dementia

2:12:38

or Alzheimer's

2:12:39

you know

2:12:40

that's another huge one

2:12:41

like traditional MSCs

2:12:42

are too big

2:12:43

to pass the blood-brain barrier

2:12:46

MUSE MSCs

2:12:47

can be internasally administered

2:12:49

and immediately go into

2:12:51

the blood-brain barrier

2:12:52

and in trials

2:12:53

they were able to see

2:12:55

the MUSE cells

2:12:56

18 months later

2:12:58

lit up like a Christmas tree

2:13:00

in the midbrain

2:13:01

the reason that's important

2:13:02

is midbrain

2:13:03

is where Parkinson's

2:13:04

and so many of these

2:13:06

neurocognitive disease states

2:13:08

reside

2:13:08

and where most of the

2:13:10

dysfunction is occurring

2:13:11

and so

2:13:13

yeah

2:13:15

there's a lot of promise

2:13:16

I'm excited about it

2:13:17

I think MUSE

2:13:18

are going to be

2:13:18

a big opportunity

2:13:20

here in America

2:13:21

to drive meaningful change

2:13:22

it's just a matter of

2:13:23

you know

2:13:23

when and how

2:13:25

they're available

2:13:26

and to what capacity

2:13:27

you're going to see

2:13:29

these things

2:13:29

springing up

2:13:30

at the state level

2:13:31

they're already happening

2:13:32

all over

2:13:33

outside the United States

2:13:34

it's just a little bit

2:13:36

different market here

2:13:37

with the regulatory landscape

2:13:39

well that's what's so frustrating

2:13:40

is that they are being utilized

2:13:42

effectively overseas

2:13:44

yeah

2:13:44

and you think about

2:13:45

how many people

2:13:46

do have people

2:13:47

that are in the hospital

2:13:48

do have chronic illness

2:13:49

do have these problems

2:13:50

that could be fixed here

2:13:52

yeah

2:13:52

and like

2:13:53

let's get it going guys

2:13:55

yeah

2:13:55

yeah

2:13:56

I'm telling you man

2:13:57

like it's

2:13:58

such an exciting time

2:13:59

it's super exciting

2:14:00

yeah

2:14:00

it's super exciting

2:14:01

and hopefully it's not too boring

2:14:02

for the listeners

2:14:03

it's just

2:14:03

it's complicated stuff

2:14:04

so I want to try to break it down

2:14:05

it's not boring at all man

2:14:07

don't apologize

2:14:08

is there anything else

2:14:09

you want to cover

2:14:10

no

2:14:10

the other is just

2:14:11

you said some of the treatments

2:14:12

you know

2:14:13

one of the ones that

2:14:14

I heard Dana White talk about

2:14:15

and he had said

2:14:16

well you got to go to Mexico

2:14:17

is plasmapheresis

2:14:19

like we have plasmapheresis

2:14:21

here in Austin, Texas

2:14:22

we use it

2:14:24

we added it to the clinic

2:14:25

I guess three months ago

2:14:27

plasmapheresis

2:14:29

is also known as

2:14:30

therapeutic plasma exchange

2:14:32

essentially we run your blood

2:14:34

through a dialysis machine

2:14:35

it's been used for over 50 years

2:14:38

it's used at the Mayo Clinic

2:14:39

it's used at all of these

2:14:40

various academic institutions

2:14:42

it just hasn't been used

2:14:44

for longevity

2:14:45

right

2:14:45

and in an insurance model

2:14:47

where you're trying to get

2:14:48

a reimbursement rate

2:14:50

you've got to have an indication

2:14:51

but in a cash pay model

2:14:53

and this is where the world

2:14:54

is your oyster

2:14:55

in a cash pay model

2:14:56

a clinician

2:14:57

and you the patient

2:14:58

can make a decision

2:14:59

that you want to get

2:15:01

proactive and predictive

2:15:02

and you want to

2:15:03

run your body

2:15:04

your blood

2:15:05

through a plasmapheresis machine

2:15:07

and basically isolate out

2:15:09

within the plasma itself

2:15:11

the liquid

2:15:12

are all the inflammatory markers

2:15:14

all the leftover

2:15:15

bad stuff

2:15:17

that you don't want

2:15:17

in your blood

2:15:18

so for me

2:15:18

as a 45 year old male

2:15:20

I've got 45 years

2:15:21

of all the attrition

2:15:22

and stuff that's in my system

2:15:24

you get 70% of that out

2:15:27

through one therapeutic

2:15:28

plasma exchange

2:15:29

utilizing the plasmapheresis machine

2:15:32

and so what we'll do is

2:15:33

we'll extrapolate out

2:15:35

systematically your plasma

2:15:37

and replace it with

2:15:38

young healthy protein

2:15:39

called albumin

2:15:40

and then where we go

2:15:42

an additional step

2:15:43

at WasteWell

2:15:44

is we're developing

2:15:45

a protocol

2:15:46

where we also add in

2:15:48

the MSCs

2:15:49

and peptides

2:15:52

and all of the things

2:15:53

that are missing

2:15:55

from albumin

2:15:56

right

2:15:56

so there's two different

2:15:57

train of thoughts

2:15:58

and I have these listed too

2:16:01

Jamie on the website

2:16:02

there's a bunch

2:16:02

of different studies

2:16:03

plasmapheresis has been studied

2:16:05

for over 50 years

2:16:06

it's just not been utilized

2:16:08

for like longevity

2:16:09

and preventative care

2:16:10

it's used more

2:16:12

for systematic

2:16:14

inflammatory issues

2:16:15

there's even a bunch

2:16:16

of fascinating studies

2:16:18

around Alzheimer's

2:16:19

because Alzheimer's

2:16:20

and dementia

2:16:20

is so inflammatory related

2:16:22

so there's a bunch

2:16:24

of fascinating stuff

2:16:25

on that

2:16:26

but the premise

2:16:26

of plasmapheresis

2:16:28

is think of it

2:16:28

like an oil change

2:16:29

for your body

2:16:30

we're going to take out

2:16:31

70% of all the bad stuff

2:16:34

that's floating around

2:16:34

in your blood

2:16:35

we're going to replace

2:16:36

that blood

2:16:37

with young healthy albumin

2:16:38

and then you know

2:16:40

what we're attempting

2:16:40

to do is stack it

2:16:41

with our own protocol

2:16:42

where we add in MSCs

2:16:45

extracellular vesicles

2:16:46

all of these cellular goodies

2:16:48

that are readily available

2:16:50

at birth

2:16:50

that have a precipitous

2:16:51

decline as we age

2:16:52

what is this

2:16:53

can serial therapy

2:16:54

lower right corner

2:16:55

plasma exchange

2:16:57

remove synthetic chemicals

2:16:58

from humans

2:16:59

so is this like BPCs

2:17:00

and that kind of shit

2:17:01

what it's yeah

2:17:03

what it's doing is

2:17:04

it's the goal

2:17:06

is to remove

2:17:07

all the extra stuff

2:17:08

that's in your system

2:17:09

that you don't need

2:17:09

and this study

2:17:10

is pretty interesting

2:17:11

because it breaks down

2:17:11

what they saw

2:17:12

here's a real world example

2:17:14

our mutual friend

2:17:15

Philip Franklin Lee

2:17:16

and I asked him

2:17:18

if I can talk about this

2:17:19

look at this

2:17:20

compounds such as

2:17:21

bisphenol

2:17:22

plasticizers

2:17:23

and phthalates

2:17:24

yep

2:17:25

endocrine disruptors

2:17:26

that are associated

2:17:26

with the intake

2:17:27

of ultra processed foods

2:17:28

due to

2:17:29

at least in part

2:17:29

to their packaging material

2:17:31

so this is the stuff

2:17:32

that Dr. Shanna Swans

2:17:33

talked about

2:17:34

that are endocrine disruptors

2:17:35

endocrine disruptors

2:17:36

so crazy

2:17:38

Philip

2:17:38

and he's talked about

2:17:40

this on his podcast

2:17:41

Philip came in

2:17:43

chronically tired

2:17:44

super low testosterone

2:17:46

I think

2:17:47

I can't remember

2:17:47

the exact number

2:17:48

he talked about

2:17:49

on his podcast

2:17:49

but he was shocked

2:17:50

how low his testosterone

2:17:51

it was like 80 or 90

2:17:53

it was really really low

2:17:54

we did a microplastics test

2:17:56

and he had the most

2:17:58

freaking microplastics

2:17:59

that we've ever seen

2:18:01

well he eats all that sushi

2:18:02

and it's always wrapped

2:18:03

in plastic

2:18:04

I know

2:18:04

and so we ran that test

2:18:06

and then it was

2:18:08

through the roof

2:18:08

and it scared him

2:18:09

and Philip

2:18:10

stopped drinking out

2:18:11

of plastic bottles

2:18:12

took a very like

2:18:14

measured approach

2:18:16

to trying to be aware

2:18:17

of how much plastic

2:18:18

he could inadvertently

2:18:19

be consuming

2:18:20

and then we ran him

2:18:21

through ways

2:18:21

to well protocols

2:18:22

not only

2:18:24

can we quantify it

2:18:25

through his testing

2:18:26

which I think he posted

2:18:27

on his Instagram

2:18:27

we quantified

2:18:29

how much we reduced

2:18:30

the level of microplastics

2:18:31

philip's testosterone

2:18:33

without being on

2:18:35

any testosterone

2:18:36

is at 1200

2:18:38

whoa

2:18:39

all of that inflammation

2:18:41

and shit

2:18:42

that was in his system

2:18:43

was causing

2:18:44

chronic inflammation

2:18:45

chronic fatigue

2:18:46

running down

2:18:47

his immune system

2:18:48

and causing

2:18:49

all of these

2:18:50

cascade effects

2:18:51

that led to him

2:18:51

essentially having

2:18:53

a low testosterone

2:18:53

how many people

2:18:54

out there

2:18:55

are having

2:18:56

a shitload

2:18:56

that's what it's like

2:18:58

like so many people

2:18:59

come in and go

2:19:00

what do you have

2:19:00

that can help me

2:19:01

and this is what's

2:19:02

challenging too

2:19:03

this is another thing

2:19:04

I want to point out

2:19:04

about the challenge

2:19:06

of like

2:19:06

not making claims

2:19:08

or understanding

2:19:09

the nuance

2:19:09

we saw this

2:19:10

with the psychedelic

2:19:11

attempt to get

2:19:12

psychedelics

2:19:13

through the FDA

2:19:13

one of the things

2:19:14

that they wanted

2:19:15

to do in the

2:19:15

psychedelic trials

2:19:16

was provide

2:19:17

psychiatric

2:19:18

what's the

2:19:20

integration

2:19:20

so you come out

2:19:21

the other end

2:19:22

of a mushroom journey

2:19:23

and you talk

2:19:24

to a therapist

2:19:25

and you walk

2:19:26

through

2:19:26

what you experience

2:19:28

to process

2:19:29

your thoughts

2:19:29

and emotions

2:19:30

the system's

2:19:32

not built

2:19:32

to do that

2:19:33

because now

2:19:33

you're taking

2:19:34

two different things

2:19:35

and attempting

2:19:36

to build a

2:19:37

bill master code

2:19:38

and get an indication

2:19:40

well if I'm united

2:19:42

I'm going to go

2:19:42

well how do I know

2:19:43

it wasn't just

2:19:44

the therapy

2:19:45

or maybe it was

2:19:46

just the mushrooms

2:19:47

why am I paying

2:19:47

the therapist

2:19:48

and so that's

2:19:49

one of the challenges

2:19:50

when people go

2:19:50

what do you have

2:19:52

for microplastics

2:19:53

what's tough

2:19:55

is a lot of people

2:19:55

come in

2:19:55

and they go

2:19:56

hey man

2:19:56

I'm going to do

2:19:57

the hockett

2:19:57

and I'm going to do

2:19:58

the plasmapheresis

2:19:59

and I want to do

2:20:01

MSCs

2:20:02

and I want you

2:20:03

to bring down

2:20:03

my inflammation

2:20:04

and so so many people

2:20:06

are doing

2:20:06

multiple modalities

2:20:07

what I'm saying

2:20:10

is it's working

2:20:11

but which one

2:20:12

is the needle mover

2:20:14

or is it an attrition

2:20:15

of all of them

2:20:16

you know

2:20:17

that's where this

2:20:18

gets tough

2:20:18

and that's where

2:20:19

I want to track

2:20:19

and do a better job

2:20:20

of like tracking

2:20:21

and quantifying

2:20:22

individuals

2:20:23

who just do one test

2:20:24

or one treatment

2:20:25

or one aspect

2:20:26

of what we're doing

2:20:27

at Weighs2Well

2:20:28

which one's moving

2:20:29

the needle the most

2:20:30

because so many people

2:20:31

want to try everything

2:20:32

right they're already here

2:20:33

they already flew in

2:20:34

so they're like

2:20:34

yeah let me do this today

2:20:36

this tomorrow

2:20:36

this and then they all

2:20:38

report back

2:20:38

I'm feeling phenomenal

2:20:39

I feel the best I've felt

2:20:40

but they did five things

2:20:42

so I don't know

2:20:43

which one

2:20:44

was the one

2:20:45

does it matter

2:20:46

as long as it's

2:20:47

providing a benefit

2:20:48

it's good to know

2:20:49

but yeah

2:20:50

listen man

2:20:51

thank you so much

2:20:52

for everything

2:20:52

I'm so happy

2:20:54

you're out there

2:20:54

and this is so exciting

2:20:56

all this stuff

2:20:56

is so exciting

2:20:57

and I'm glad

2:20:58

we have another opportunity

2:20:59

to talk to people

2:21:00

about this shit

2:21:01

because it's really

2:21:02

impactful

2:21:02

you're the man

2:21:04

and if you wouldn't

2:21:04

have had me on here

2:21:05

to talk about this

2:21:06

I wouldn't have got

2:21:07

to meet Secretary Kennedy

2:21:08

and we wouldn't

2:21:09

be in a position

2:21:10

and I will tell you

2:21:11

not being hyperbolic

2:21:12

if you weren't here

2:21:15

and fighting

2:21:16

for peptides

2:21:17

and accessibility

2:21:17

and you hadn't

2:21:19

given me a platform

2:21:20

I don't know

2:21:21

if anybody

2:21:22

would be

2:21:23

helping this administration

2:21:25

navigate all this

2:21:26

I really don't

2:21:27

there's so many people

2:21:28

on the opposite side

2:21:29

of the aisle

2:21:29

that it's a tough

2:21:32

thing to navigate

2:21:32

and it takes

2:21:33

somebody who knows

2:21:34

and has been in the industry

2:21:35

enough to explain it

2:21:36

hopefully in a way

2:21:37

that resonates

2:21:38

where we can get

2:21:40

things done

2:21:40

but we'll see

2:21:41

well it's exciting

2:21:43

yeah

2:21:43

thank you man

2:21:44

thanks brother

2:21:45

appreciate you

2:21:45

bye everybody